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ABSTRACT 
 
 
 
Creatine plays essential roles in energy metabolism by the interconversion, by creatine kinase, 
to its phosphorylated analogue, phosphocreatine, allowing the regeneration of ATP. Creatine 
is synthesized in mammals by a two step mechanism involving arginine:glycine 
amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT). Creatine is 
taken up by cells by a specific transporter, SLC6A8. 
Creatine deficiency syndromes, due to defects in GAMT, AGAT and SLC6A8, are among the 
most frequent inborn errors of metabolism, and are characterized by an absence or a severe 
decrease of creatine in central nervous system, which is the main tissue affected. While it is 
known that AGAT, GAMT and SLC6A8 are expressed in CNS, many questions remain on 
the specific effects of AGAT, GAMT and SLC6A8 deficiencies on brain cells. Our aim was 
to develop new experimental models of creatine deficiencies by knockdown of GAMT and 
SLC6A8 genes by RNAi in 3D organotypic rat brain cell cultures in aggregates. 
Specific shRNAs for the GAMT and SLC6A8 genes were transduced in brain cell aggregates 
by adeno-associated viruses (AAV). The AAV-transduced shRNAs were able to efficiently 
knockdown the expression of our genes of interest, as shown by a strong decrease of protein 
by western blotting, a decrease of mRNA by qPCR or characteristic variations of creatine and 
guanidinoacetate by tandem mass spectrometry.  
After having validated our experimental models, we have also shown that GAMT and 
SLC6A8 knockdown affected the development of astrocytes and neurons or oligodendrocytes 
and astrocytes, respectively. We also observed an increase of cell death and variations in 
activation pattern of caspase 3 and p38 MAPK pathways, involved in apoptosis, in our 
experimental model. 
  
 
iv 
RESUME 
 
 
 
La créatine joue un rôle essentiel dans le métabolisme cellulaire par sa conversion, par la 
creatine kinase, en phosphocreatine permettant la régénération de l’ATP. La synthèse de 
créatine, chez les mammifères, s’effectue par une réaction en deux étapes impliquant 
l’arginine:glycine amidinotransférase (AGAT) et la guanidinoacétate méthyltransférase 
(GAMT). L’entrée de créatine dans les cellules s’effectue par son transporteur, SLC6A8. 
Les déficiences en créatine, dues au déficit en GAMT, AGAT ou SLC6A8, sont fréquentes et 
caractérisées par une absence ou une forte baisse de créatine dans le système nerveux central. 
Alors qu'il est connu que AGAT, GAMT et SLC6A8 sont exprimés par le cerveau, les 
conséquences des déficiences en créatine sur les cellules nerveuses sont peu comprises. Le but 
de ce travail était de développer de nouveaux modèles expérimentaux des déficiences en Cr 
dans des cultures 3D de cellules nerveuses de rat en agrégats au moyen de l’interférence à 
l’ARN appliquée aux gènes GAMT et SLC6A8. 
Des séquences interférentes (shRNAs) pour les gènes GAMT et SLC6A8 ont été transduites 
par des vecteurs viraux AAV (virus adéno-associés), dans les cellules nerveuses en agrégats. 
Nous avons ainsi démontré une baisse de l’expression de GAMT au niveau protéique (mesuré 
par western blot), et ARN messager (mesuré par qPCR) ainsi qu’une variation caractérisitique 
de créatine et guanidinoacétate (mesuré par spectrométrie de masse). 
Après avoir validé nos modèles, nous avons montré que les knockdown de GAMT ou 
SLC6A8 affectent le développement des astrocytes et des neurones ou des oligodendrocytes 
et des astrocytes, respectivement, ainsi qu’une augmentation de la mort cellulaire et des 
modifications dans le pattern d’activation des voies de signalisation impliquant caspase 3 et 
p38 MAPK, ayant un rôle dans le processus d’apoptose. 
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I. Creatine deficiency syndromes 
 
 
1. Creatine metabolism and transport 
 
Creatine (Cr) ( -N-methylguanidino acetic acid) is a nitrogenous organic amino acid playing 
essential roles to maintain energy levels in most tissues, and is highly active in particular in 
those with high and/or fluctuating energy demand such as skeletal muscle, heart and brain 
(Wallimann et al., 1992). The Cr/phosphocreatine (PCr)/creatine kinase (CK) system not only 
serves as intracellular buffer for ATP, but also as high-energy phosphate shuttle from 
mitochondrial sites of production to cytoplasmic sites of consumption (Figure 1). 
 
Part of intracellular Cr is converted by CK into the high-energy compound PCr. Four CK 
isoforms have been described, based on tissue expression and subcellular distribution: two 
cytosolic forms, M-CK (in muscle) and B-CK (in brain) and two mitochondrial forms, 
sarcomeric muscle form (sMtCK) and brain form called ubiquitous MtCK (uMtCK) 
(Schlattner et al., 2006; Wallimann et al., 1992). Each CK isoform has a specific function, 
mitochondrial CKs using ATP to convert Cr to its high energy phosphorylated analogue PCr 
for export to cytoplasm, and cytosolic CKs using PCr to convert ADP to ATP by the transfer 
of N-phosphoryl group at sites of energy demand, and to convert excess ATP to PCr for 
energy storage (Wallimann et al., 1992; Wallimann et al., 1998). 
 
  
 
5 
 
Figure 1 : Synthesis and function of creatine (Cr). Cr synthesis requires the presence of two enzymes, L-
arginine: glycine amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT); cells take up Cr 
by a specific transporter, SLC6A8. Mitochondrial or cytosolic creatine kinase (CK) convert Cr to its high-energy 
counterpart phosphocreatine (PCr). PCr dephosphorylation yields energy, as ADP is converted to ATP. Besides 
its function in cellular energy, Cr may also be involved in neurotransmission (figure taken from Béard and 
Braissant, 2010). 
 
 
Total Cr (Cr + PCr) in 70kg young adults amounts for approximately 120g. Both Cr and PCr 
are non-enzymatically and irreversibly degraded to creatinine at a rate of about 1.7% of total 
body pool per day (Wyss and Kaddurah-Daouk, 2000). Creatinine is excreted via kidneys, the 
amount of creatinine eliminated being proportional to muscle. The amount of Cr needed to 
renew the degraded one, depends on creatinine excretion but accounts for about 2g/day 
(Casey and Greenhaff, 2000). 
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In human, half of Cr stores originate from food, mainly fresh meat, fish and dairy products, 
while the other half is biosynthesized endogenously through a pathway involving two 
enzymes: L-arginine:glycine amidinotransferase (AGAT) and guanidinoacetate 
methyltransferase (GAMT). From the precursors arginine (limiting factor) and glycine, 
AGAT catalyzes the formation of guanidinoacetate (GAA) and ornithine. This step occurs 
mostly in kidney where Cr level exerts a negative feedback loop on AGAT gene regulation at 
the transcriptional level (Brosnan et al., 2009; McGuire et al., 1984). The second reaction, 
catalyzed by GAMT and occurring mostly in liver, uses S-adenosylmethionine to methylate 
GAA, producing Cr and S-adenosylhomocysteine (Brosnan et al., 2009). AGAT and GAMT 
expression are positively regulated by growth hormone, thyroid hormone and sex hormones 
(Carlson and Van Pilsum, 1973; Guthmiller et al., 1994; Lee et al., 1994; McGuire et al., 
1984). While AGAT and GAMT highest expression is found in kidney and liver, respectively, 
they are also expressed at lower levels in various other tissues, including CNS (Braissant et 
al., 2001; Lee et al., 1998; Wyss and Kaddurah-Daouk, 2000).  
 
Creatine is transported by blood to Cr-requiring tissues, and taken up in cells with high energy 
demand by a Cr-specific transporter, SLC6A8. SLC6A8 is a member of the solute carrier 
family 6, a large family of membrane transporters that mediate the transport of various 
neurotransmitters and/or amino acids across plasma membrane with the co-transport of two 
Na+ and one Cl- (Chen et al., 2004). This transport is electrogenic and driven by the sodium 
gradient established by Na+/K+-ATPase (Dai et al., 1999). SLC6A8 expression is important in 
tissues with high energy demand, such as skeletal muscle, heart, brain, retina, or with 
important (re)absorptive functions, such as kidney and intestine (Braissant et al., 2001; 
Guimbal and Kilimann, 1993; Mak et al., 2009; Peral et al., 2002). Cr uptake is regulated by 
different factors, like insulin which activates Na+/K+-ATPase and presumably increases the 
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driving force for Cr uptake (Snow and Murphy, 2001), or the Na+ gradient and intracellular Cr 
concentration (Brosnan and Brosnan, 2007). 
 
2. Creatine metabolism, transport and functions in the brain 
 
2.1. Functions of creatine in CNS 
 
The Cr/PCr/CK system plays essential roles in the brain to maintain the high energy levels 
necessary for CNS (maintenance of membrane potential and ions gradient,  Ca++ homeostasis, 
neurotransmission, intracellular signaling systems as well as axonal and dendritic transport) 
(Wyss and Kaddurah-Daouk, 2000). The brain represents only 2% of the body mass but may 
spend up to 20% of total energy consumption. The Cr/PCr/CK system also plays essential 
roles in CNS during development. Different studies showed that CK isoforms are found 
highly concentrated in cerebellum (especially in glomeruli structures of cerebellar granular 
layer), choroid plexus and in hippocampal granular and pyramidal cells (Hemmer et al., 
1994). It must be noted that hippocampus is important for learning and memory function and 
can be severely affected in Alzheimer’s disease (AD). B-CK is much higher than uMtCK in 
cerebellar Bergmann glial cells and hypothalamus, where it plays essential functions in 
regenerating ATP for glutamate clearance during excitatory synaptic transmission (Oliet et 
al., 2001). Knock-out for one CK isoform (B-CK or uMt-CK) showed behavioral 
abnormalities and defects in formation and maintenance of hippocampal mossy fiber 
connections. Double knockout mice displayed decreased body weight and severely impaired 
spatial learning, lower nest building activity and reduction of hippocampal size (Jost et al., 
2002; Streijger et al., 2005). All these studies demonstrate the key function of CK in brain 
energy metabolism (Hemmer and Wallimann, 1993).  
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Apart of its functions in energy, Cr may play other roles, as recently been suggested in 
particular in CNS. Cr was suggested as essential CNS osmolyte. Astrocytes placed in 
hyperosmotic shock significantly increase their Cr uptake, suggesting that Cr can work as 
compensatory osmolyte (Alfieri et al., 2006). Conversely, astrocytes exposed to hypo-osmotic 
swelling conditions stimulate the release of their osmotically active Cr (Bothwell et al., 2001). 
In contrast, ammonium-exposed microcapillary endothelial cells (MCEC) in vitro stimulate 
their Cr uptake (Belanger et al., 2007), suggesting that the cells making blood-brain barrier 
(BBB) (MCEC and astrocytes lining them) behave differentially during swelling. Cr was also 
proposed as appetite and weight regulator, by acting on specific hypothalamic nuclei 
(Galbraith et al., 2006). 
 
 
2.2. Creatine: a co-transmitter in CNS? 
 
Creatine and GAA can affect GABAergic neurotransmission as partial agonists on post-
synaptic GABAA receptors, depending on local GABA concentration (Cupello et al., 2008; 
De Deyn et al., 1991; Neu et al., 2002). These data stimulated research showing that in 
organotypic cultures of rat cortex, caudate putamen and hippocampus slices, Cr is released 
from neurons in a similar manner as classical neurotransmitters. This electrically-evoked 
exocytotic Cr release mechanism is action potential-dependent, being dependent from Ca2+, 
inhibited by the Na+-channel blocker tetrodotoxin and enhanced by the K+-channel blocker 4-
amino-pyridine (Almeida et al., 2006b). According to these in vitro studies, Cr may thus also 
be considered as a neuromodulator or co-transmitter in CNS, which may modulate the activity 
of post-synaptic receptors such as GABAA (Almeida et al., 2006a). Interestingly, rat brain 
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synaptosomes were identified recently as expressing SLC6A8, which allows their active 
accumulation of Cr (Peral et al., 2010). This suggests the presence of a Cr recapture 
mechanism in axon terminal membrane, which would fit with a neurotransmitter/co-
transmitter function of Cr in CNS (Almeida et al., 2006a). 
 
2.3. AGAT, GAMT and SLC6A8 in the adult brain 
 
It has long been thought that most of the brain Cr was of peripheral origin, be it taken from 
the diet or synthesized endogenously through AGAT and GAMT activities in kidney and liver 
respectively (Brosnan and Brosnan, 2007; da Silva et al., 2009; Wyss and Kaddurah-Daouk, 
2000). However, Cr is synthesized in the mammalian brain (Van Pilsum et al., 1972) as well 
as in primary brain cell cultures and nerve cell lines (Braissant et al., 2002; Daly, 1985; 
Dringen et al., 1998). AGAT and GAMT are expressed in CNS, for which we provided the 
first detailed analysis demonstrating their expression in all the main structures of the adult rat 
brain, in every main cell types (neurons, astrocytes and oligodendrocytes; Braissant et al., 
2001) (Figure 2). Particularly high levels were found in telencephalon and cerebellum. AGAT 
was further shown in rat retina (Nakashima et al., 2005), while our data on GAMT were 
confirmed in mouse and human (Schmidt et al., 2004; Tachikawa et al., 2004). 
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Figure 2 : Model of Cr synthesis and transport in CNS, illustrating the diversity of AGAT, GAMT and 
SLC6A8 expression by brain cells (figure taken from Béard and Braissant, 2010). 1) Cr endogenous synthesis 
within cells co-expressing AGAT and GAMT. 2) Cr endogenous synthesis through AGAT-expressing cells 
synthesizing GAA, and GAA uptake by SLC6A8 in GAMT-expressing cells. 3) Cell expressing only SLC6A8 
(“users” of Cr). 4) Cells silent for AGAT, GAMT and SLC6A8. While microcapillaries express SLC6A8, 
astrocytic feet lining them do not. This implies that only low amounts of peripheral Cr can enter the brain 
through the limited endothelial surface that is free of astrocytic feet, and that CNS must also ensure its own 
endogenous synthesis of Cr. So far, the way Cr (and GAA) can leave cells is poorly known. Cr, creatine; AGAT, 
L-arginine: glycine amidinotransferase; GAMT, guanidinoacetate methyltransferase; GAA, guanidinoacetate; 
SLC6A8, Cr transporter. 
 
 
Organotypic rat cortical cultures, primary brain cell cultures (neuronal, glial or mixed) and 
neuroblastoma cell lines have a Cr transport activity (Almeida et al., 2006b; Braissant and 
Henry, 2008; Daly, 1985; Möller and Hamprecht, 1989). In vivo, mouse and rat CNS can take 
up Cr from the blood against its concentration gradient (Ohtsuki et al., 2002; Perasso et al., 
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2003). SLC6A8 is expressed throughout the main regions of the adult mammalian brain, 
particularly in those associated with learning, memory and general limbic functions (Guimbal 
and Kilimann, 1993; Happe and Murrin, 1995; Saltarelli et al., 1996; Schloss et al., 1994). We 
provided the first detailed analysis demonstrating that SLC6A8 is found in neurons and 
oligodendrocytes but, in contrast to AGAT and GAMT, cannot be detected in astrocytes 
(Braissant et al., 2001). We also showed that in contrast to its absence in astrocytes lining 
microcapillaries, SLC6A8 is present in MCEC (BBB; Figure 2). These data were confirmed 
later in rat and mouse (Acosta et al., 2005; Mak et al., 2009; Nakashima et al., 2004; Ohtsuki 
et al., 2002; Tachikawa et al., 2004; Tachikawa et al., 2008). 
 
 
2.4. AGAT, GAMT and SLC6A8 in the developing brain 
 
The Cr/PCr/CK system plays essential roles in energy homeostasis during vertebrate 
embryonic development (Wallimann et al., 1992). Many structures of the vertebrate embryo 
express CKs at early stages (Dickmeis et al., 2001; Lyons et al., 1991), and Cr concentrations 
between 5 and 8 mmol/kg wet weight have been measured in CNS of rat and human fetus 
(Kreis et al., 2002; Miller et al., 2000). Parts of CNS developmental needs for Cr are provided 
by active transport of Cr from mother to embryo, Cr accumulating in chorioallantoic placenta 
and yolk sac at concentrations higher than found in maternal and fetal blood, then diffusing 
down its concentration gradient into fetal circulation (Davis et al., 1978). 
 
AGAT, GAMT and SLC6A8 are well expressed during vertebrate embryogenesis (Braissant 
et al., 2005; Ireland et al., 2009; Sandell et al., 2003; Schloss et al., 1994; Schmidt et al., 
2004; Wang et al., 2007), and probably play essential roles in developing CNS as their 
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deficiencies lead to neurological symptoms in early infancy and severe neurodevelopmental 
delay (see below). 
Working on the rat, we have provided the first detailed analysis of AGAT, GAMT and 
SLC6A8 expression in the developing embryonic CNS (Braissant et al., 2005). AGAT and 
GAMT are expressed in the whole developing CNS parenchyma. However, their low level 
(GAMT in particular) at early developmental stages suggests that embryonic CNS depends on 
external Cr supply, be it from embryonic periphery or from maternal origin. This is coherent 
with SLC6A8 expression in whole embryonic CNS already at early stages (E12.5 in the rat), 
with particularly high levels in ventricular zone and in choroid plexus, the predominant 
metabolic exchange zone of fetal brain before differentiation of BBB (Braissant et al., 2005; 
Braissant et al., 2007). 
 
 
2.5. Functions of AGAT, GAMT and SLC6A8 in CNS: synthesis or uptake of 
creatine by the brain? 
 
Total Cr levels and CK activity are well correlated in mammalian CNS (Wyss and Kaddurah-
Daouk, 2000), their highest levels being reached in brain cells described with high and 
fluctuating energy demands, where AGAT, GAMT and SLC6A8 are expressed (Braissant et 
al., 2007; Hemmer et al., 1994; Wang and Li, 1998). 
 
SLC6A8 absence in astrocytes, particularly in their feet sheathing MCEC, made us suggest 
that in the mature brain, BBB has a limited permeability for Cr, despite SLC6A8 expression 
by MCEC and their capacity to import Cr (Braissant et al., 2001; Braissant et al., 2007; 
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Braissant, 2012). In vivo data confirmed this hypothesis: the blood to brain transport of Cr is 
effective in rodents, but is relatively inefficient (Ohtsuki et al., 2002; Perasso et al., 2003), 
and long term treatment of AGAT- and GAMT-deficient patients with high doses of Cr 
allows a very slow and in most cases partial replenishement of their CNS Cr (Schulze and 
Battini, 2007; Stöckler et al., 2007). Consequently, the brain may depend more on its own Cr 
synthesis through AGAT and GAMT expression than on Cr supply from the blood (Braissant 
et al., 2007; Braissant and Henry, 2008). The effective but limited passage of Cr from blood 
to CNS through BBB may occur through the limited surface of CNS microcapillary 
endothelium that is free of astrocytic feet (Ohtsuki, 2004; Virgintino et al., 1997) (Figure 2). 
 
One strong argument in favor of the “brain endogenous Cr synthesis” hypothesis comes from 
Cr measures in CSF of Cr-deficient patient (see Braissant and Henry 2008; and references 
therein). SLC6A8-deficient patients present normal Cr levels in CSF, but cannot import it 
from periphery (Cecil et al., 2001; de Grauw et al., 2002). In contrast, GAMT-deficient 
patients show strongly decreased Cr levels in CSF, but can import it from blood (Schulze et 
al., 1997). This also suggests that CNS Cr synthesis might still remain operational, although 
very partially, under SLC6A8 deficiency, while it is completely blocked in AGAT and 
GAMT deficiencies. Endogenous synthesis or a very efficient uptake from periphery are the 
two ways available for the brain to secure Cr homeostasis for its energy and functions. As 
uptake from periphery does not appear efficient, CNS might privilege Cr endogenous 
synthesis (Braissant, 2012). 
 
The “brain endogenous Cr synthesis” hypothesis might seem contradictory with in vivo 
characteristics of SLC6A8 deficiency, which, despite AGAT and GAMT expression in CNS, 
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shows an absence (or a very low level) of brain Cr by magnetic resonance spectroscopy 
(MRS) (Salomons et al., 2001). This apparent contradiction is probably explained by AGAT, 
GAMT and SLC6A8 expression patterns in CNS. AGAT and GAMT are found in every CNS 
cell type (Braissant et al., 2001), but appear rarely co-expressed within the same cell 
(Braissant et al., 2010). This suggests that to allow Cr synthesis in the brain, GAA must be 
transported from AGAT to GAMT-expressing cells (Braissant and Henry, 2008) (Figure 2). 
This GAA transfer most propably occurs through SLC6A8, as recently shown by Cr and 
GAA competition studies, and the use of stable isotope-labelled GAA demonstrating its 
conversion to Cr by GAMT activity (Braissant et al., 2010). These observations may explain 
the absence of Cr in CNS of SLC6A8-deficient patient, despite normal expression of AGAT 
and GAMT in their brain (Braissant and Henry, 2008). Recent studies also demonstrate the 
importance of SLC6A8 (and taurine transporter) for the GAA transport across BBB and at 
blood-cerebrospinal fluid (CSF) barrier, as well as in brain parenchymal cells (Tachikawa et 
al., 2008; Tachikawa et al., 2009; Braissant, 2012).  
 
While we have shown that AGAT and GAMT can be found in all brain cell types (Braissant 
et al., 2009), various studies demonstrated high levels of GAMT within glial cells (Braissant 
et al., 2008; Schmidt et al., 2004; Tachikawa et al., 2004), suggesting that the final CNS step 
for Cr synthesis may predominantly by glial. However, this probably depends on the CNS 
region considered, as in cortex, only 20% of astrocytes express GAMT, in comparison with 
48% of neurons (Braissant et al., 2010). 
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3. Creatine deficiency syndromes  
 
Inborn errors of Cr biosynthesis and transport, called Cr deficiency syndromes and due to 
deficiencies in AGAT, GAMT and SLC6A8 (Figures 3-5), are characterized by an absence or 
a severe decrease of Cr in CNS, as measured by MRS (Item et al., 2001; Salomons et al., 
2001; Stöckler et al., 1994; Stromberger et al., 2003). AGAT and GAMT deficiencies are 
autosomal recessive diseases, while SLC6A8 deficiency is a X-linked disorder. Cr deficiency 
syndromes appear among the most frequent inborn errors of metabolism (IEM), the 
prevalence of SLC6A8 deficiency being estimated at 2% of all X-linked mental retardations 
(Rosenberg et al., 2004) and at 1% of males with mental retardation of unknown etiology 
(Clark et al., 2006). AGAT and GAMT deficiencies appear rarer. The prevalence of all 
combined Cr deficiencies was estimated at 2.7% of all mental retardation (Lion-François et 
al., 2006). CNS is the main organ affected in Cr deficiency syndromes, whose patients show 
severe neurodevelopmental delay and develop, in early infancy, mental retardation, 
disturbance of active and comprehensible speech, autism, and automutilating behavior 
(Battini et al., 2002; de Grauw et al., 2002; Schulze et al., 1997; Stöckler et al., 1996b). No 
significative effects have been observed in peripheral tissues with high-energy demand (e.g. 
muscle and heart) in creatine deficient patients, except a faint muscular hypotonia in very rare 
cases of GAMT deficiency. Patients with GAMT deficiency exhibit a more complex 
phenotype, including intractable epilepsy, extrapyramidal movement syndromes and 
abnormalities in basal ganglia (Mercimek-Mahmutoglu et al., 2006; Schulze, 2003; 
Stromberger et al., 2003). GAMT-deficient patients accumulates GAA because of the block in 
GAMT enzymatic activity, including in the brain where GAA accumulation is probably due 
to the combined CNS endogenous AGAT activity (Braissant and Henry, 2008), as well as to a 
facilitated crossing of BBB by GAA due to increased GAA versus decreased Cr in their blood 
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(Tachikawa et al., 2004) (Figure 4). GAA toxicity in CNS, and particularly its epileptogenic 
action (Schulze et al., 2001), may occur through disturbances of GABAergic 
neurotransmission (see above) (Neu et al., 2002).  GAA may also inhibit the complex 
between Na+/K+-ATPase and CK (Zugno et al., 2006). Severe epilepsy may also appear in 
SLC6A8-deficient patients (Mancardi et al., 2007). This may be due to the observed CNS 
GAA accumulation in some SLC6A8-deficient patients (Sijens et al., 2005), that could be 
caused by impairment of GAA transport, through deficient SLC6A8, from AGAT- to GAMT-
expressing cells (Braissant et al., 2010) (Figure 5). 
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Figure 3 : Model of AGAT deficiency in CNS. See Fig. 2 for abbreviations (figure taken from Béard and 
Braissant, 2010). 
 
 
 
 
 
Figure 4: Model of GAMT deficiency in CNS. See Fig. 2 for abbreviations (figure taken from Béard and 
Braissant, 2010). 
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Figure 5: Model of SLC6A8 deficiency in CNS. See Fig. 2 for abbreviations (figure taken from Béard and 
Braissant, 2010). 
 
 
The diverse phenotypic neurological spectrum observed in Cr deficiency syndromes show the 
importance of Cr for psychomotor development and cognitive functions and might be 
explained by the wide pattern of AGAT, GAMT and SLC6A8 genes in the mammalian brain 
(Figures 2-5), which has been documented in every main regions of rat (AGAT, GAMT and 
SLC6A8), mouse (GAMT and SLC6A8) and human (GAMT) CNS (see above). The potential 
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role of Cr as co-transmitter on the widely distributed GABA post-synaptic receptors (Almeida 
et al., 2006b) might also contribute to this phenotypic diversity.  
AGAT and GAMT patients can be treated with Cr, which strongly improves their 
neurological status and CNS development (Battini et al., 2002; Item et al., 2001; Schulze et 
al., 1998; Stöckler et al., 1996a) (Figures 3 and 4). For GAMT-deficient patients, combined 
arginine restriction and ornithine substitution coupled to Cr treatment decrease GAA and 
improve clinical outcomes (Schulze et al., 1998; Schulze et al., 2001; Schulze, 2003). 
However, despite improvement of clinical outcome by Cr supplementation, most AGAT- and 
GAMT-deficient patients remain with CNS developmental problems. Oral supplementation of 
Cr is inefficient in replenishing CNS Cr in SLC6A8-deficient patients (Figure 5), who remain 
with mental retardation, severe speech impairment, and progressive brain atrophy (Bizzi et al., 
2002; Cecil et al., 2001; de Grauw et al., 2002). Attempts to treat several SLC6A8-deficient 
patients with arginine and glycine as precursor of Cr gave encouraging results in the muscular 
symptoms of the disease during the first months of treatment (Chilosi A. et al., 2008; 
Valayannopoulos et al., 2011; van de Kamp et al., 2011; Wilcken B. et al., 2008), while it 
failed to improve the neurological status of four others patients (Fons et al., 2008). The use of 
a lipophilic Cr-derived compound, creatine ethyl ester, failed to replenish brain Cr 
concentration in SLC6A8-deficient patients, as well as to improve their neurological status 
(Fons et al., 2010). 
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4. Pre-symptomatic treatment of AGAT- and GAMT-deficient 
patients 
 
Two recent studies have shown that the pre-symptomatic treatment of AGAT and GAMT 
deficiencies appears to prevent the phenotypic expression of these diseases (Schulze and 
Battini, 2007). An AGAT-deficient boy, brother of two already affected AGAT-deficient 
sisters, was diagnosed at birth with the same homozygous mutation as his sisters, and treated 
orally since the age of 4 months with Cr monohydrate (Battini et al., 2006). Similarly, a 
GAMT-deficient girl, sister of an already affected GAMT-deficient brother, was diagnosed at 
birth with the same heterozygous mutations as her brother, and treated orally since the age of 
22 days with Cr monohydrate (Schulze et al., 2006). Both patients, over a follow-up of more 
than 2 years, did not develop the characteristic CNS phenotypic expression of AGAT and 
GAMT deficiencies (Schulze and Battini, 2007). These two cases suggest that Cr plays 
essential roles in the development of CNS higher cognitive functions, like speech acquisition, 
during the first months and years of life, and that treatment with Cr before irreversible 
damage occurs may prevent clinical symptoms of AGAT and GAMT deficiencies 
permanently. As described above, the pre-symptomatic treatment with Cr in postnatal stages 
and during the first years of life may also facilitate the entry of Cr into the brain, at stages 
where BBB is not as tightly regulated as in more mature stages (Engelhardt, 2003; Virgintino 
et al., 1997; Braissant, 2012), and where SLC6A8 expression on BBB and choroid plexus 
may still facilitate entry of peripheral Cr into the brain (Braissant et al., 2005; Ireland et al., 
2009), in contrast to adulthood (Braissant et al., 2001). 
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5. The GAMT -/- mouse 
 
Two in vivo models of Cr deficiencies have been described so far: the GAMT and SLC6A8 
knock-out (KO) mice.  
The GAMT KO mouse (GAMT -/-) was generated by removing the first exon of the murine 
GAMT gene (Schmidt et al., 2004). As GAMT-deficient patients, GAMT-/- mice have 
markedly decreased Cr and increased GAA levels in CNS and in body fluids (urine, serum 
and CSF) (Renema et al., 2003), and slowly replenish their brain Cr when fed with Cr.  
GAMT -/- mice show increased neonatal mortality, muscular hypotonia and decreased male 
fertility. The most obvious symptom observed is a reduction of body weight throughout life, 
more pronounced in females than males. While biochemical alterations of GAMT -/- mice are 
comparable to those found in GAMT-deficient patients, their neurological and behavioral 
analysis reveals only mild cognitive impairment and no severe neurological symptoms  
despite the important accumulation of GAA in the brain (Schmidt et al., 2004; Torremans et 
al., 2005). In particular, no severe symptoms like epileptic seizures or ataxia are observed. 
One explanation for this contrast to GAMT-deficient patients may be the use of GAA as CK 
substrate, leading to the formation of phosphorylated GAA which may play the same role as 
PCr in providing high-energy phosphates (Ellington, 2001; Renema et al., 2003). If this were 
true, the same compensation mechanism by GAA may also occur in GAMT-deficient 
patients, who can accumulate phosphorylated GAA at least in their muscle (Ensenauer et al., 
2004; Schulze, 2003).  
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6. The SLC6A8 knock-out mouse 
 
An in vivo model of SLC6A8 deficiency was very recently generated by Skelton et al. (2011). 
This transgenic mouse was generated with the Cre/loxP recombination system, and consists of 
the removal of exons 2-4 of SLC6A8 gene. As SLC6A8-deficient patients, SLC6A8 KO mice 
have no detectable levels of Cr in CNS and show cognitive impairments across a variety of 
learning and memory tests (spatial and memory deficits during Morris water maze as well as 
novel object recognition tests). In these mice, the only pathway that was found significantly 
affected was a disruption of the serotoninergic neurotransmitter system, with an increase of 
serotonin (5-hydroxytryptamine or 5-HT) in hippocampus and prefrontal cortex (Skelton et 
al., 2011). This may explain some of the learning and memory deficits observed in SLC6A8-
deficient patients, as an increase of 5-HT may alter neuronal structure as well as behavior 
(Alvarez et al., 2002; Scott et al., 2008). 
 
 
7. The AGAT -/- mice 
 
AGAT -/- KO mice have been developed recently but nothing has been published so far on the 
neurological and behavioral effects due to their Cr deficiency (Craigen et al., 2011; Sinha et 
al., 2011). 
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II. RNA interference 
 
 
1. Origins of RNA interference 
 
RNA interference is an evolutionary-conserved process found in many eukaryotic organisms, 
by which double stranded small interfering RNAs (siRNAs) lead to the degradation of their 
complementary messenger RNAs. Subsequently, this pathway leads to a decrease of the 
proteins translated from their respective mRNAs (Almeida and Allshire, 2005). RNAi is a 
cellular surveillance phenomenon that can repress viral infection, interfere with transposable 
elements and avoid the occurrence of repetitive genes (transgenes). This mechanism can also 
regulate gene expression and normal cell development (Bitko and Barik, 2001).  
Napoli and Jorgensen were the first to report an RNAi-type of phenomenon in 1990, named 
“cosuppression” (Napoli et al., 1990). In petunias, they overexpressed an enzyme, chalcone 
synthase, involved in the anthocyanin biosynthesis pathway and responsible for the petunia’s 
deep violet coloration. They expected to generate violet petunias but the flowers unexpectedly 
flourished in white. After molecular analysis, they showed that levels of endogenous chalcone 
synthase were 50-fold lower than in wild-type petunias, leading them to hypothesize that 
introduced transgene was “cosuppressing” endogenous chalcone synthase (Napoli et al., 
1990). In 1992, Romano and Macino reported a similar phenomenon in Neurospora crassa, 
noting that introduction of homologous RNA sequences caused repression of the endogenous 
gene (Romano and Macino, 1992). 
In 1998, the phenomenon of RNA interference (RNAi) was studied in another organism, 
Caenorhabditis elegans, by Fire et al., who reported that injection of double-stranded RNA 
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(dsRNA) led to an efficient sequence-specific gene silencing in the whole organism (Fire et 
al., 1998). 
The RNAi mechanism was first elucidated by using extracts of Drosophila melanogaster 
embryo which led to the identification of the key factors of RNAi response, the dsRNA 
processing enzyme Dicer and the RNA-induced silencing complex (RISC) (Hammond et al., 
2000). Briefly, the first step consists in generating small specific dsRNAs by Dicer (Figure 6), 
while in the second step RISC executes RNAi by using dsRNAs as guidance molecules to 
target the homologous, endogenous mRNA for degradation (Elbashir et al., 2001b; Hannon, 
2002; Zamore et al., 2000). In mammalian cells, dsRNA longer than 30 base pairs (bp) trigger 
the antiviral/interferon pathways, which results in global shut-down of protein synthesis (Gil 
and Esteban, 2000). RNAi-mediated gene silencing can be obtained in mammalian cell 
cultures by delivery of either chemically-synthesized short (< 30 nucleotides) double-stranded 
siRNAs (Elbashir et al., 2001a) or by endogenous expression of short hairpin RNAs 
(shRNAs) with fold-back stem-loop structure (Brummelkamp et al., 2002; Elbashir et al., 
2002; Paddison et al., 2002). 
 
 
2. Mechanisms of RNA interference 
  
The precise mechanism of RNAi has not been fully elucidated. Hannon et al. have described 
this mechanism as a dsRNA-mediated process of a sequence-specific mRNA degradation of 
the target gene, which involves initiation and execution steps (Aagaard and Rossi, 2007; 
Angaji et al., 2010; Hannon, 2002; Sharp, 2001).  
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2.1. Initiation step 
 
Depending on the organism, RNAi is triggered by various types of molecule, including 
experimentally long dsRNAs, aberrantly expressed transgenes, transposons, viral DNA, 
plasmid-based shRNAs or endogenous micro RNAs (miRNAs) (Hannon, 2002). In the 
initiation step, these molecules are processed in Dicer by its ribonuclease-III activity (Figure 
6), to generate 21-22 nucleotides small interfering RNAs (siRNAs), usually with 2-3 
nucleotides 3’-overhangs on each strand (Figure 7) (Aagaard and Rossi, 2007; Bernstein et 
al., 2001; Elbashir et al., 2001a). 
Dicer is a member of the ribonuclease III superfamily of dsRNA-specific endoribonuclease 
and contains two RNase III domains and one Piwi/Argonaute/Zwille (PAZ) domain 
(characteristic domain of RISC) (Bernstein et al., 2003); the distance between these two 
regions of the molecule determines the length of the siRNAs it produces (Figure 6) (Macrae et 
al., 2006). Dicer is present in many eukaryotic organisms including plants (Golden et al., 
2002), C. elegans (Knight and Bass, 2001), Drosophila (Bernstein et al., 2001), mouse 
(Bernstein et al., 2003) and human (Provost et al., 2002), suggesting that all these organisms 
use the same basic mechanism to initiate the RNAi pathway. 
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Figure 6: The image shows the structure of Dicer, an enzyme that cleaves RNA. New studies have revealed 
that Dicer carefully measures and snips strands of RNA into precise increments. When Dicer cuts large strands 
of RNA into smaller fragments, it initiates the process of RNA interference, which can turn genes off and 
thereby dictate key developmental events (figure taken from Macrae et al, 2006). 
 
 
2.2. Execution step 
 
In this next step, the siRNA generated by Dicer gets incorporated into the multiprotein RISC 
present in cytosol (Hannon, 2002). RISC contains a helicase protein and becomes activated 
after unwinding the double-stranded siRNA into single-stranded RNA. RISC uses the 
sequence of the antisense strand of the siRNA, retained in this complex, to identify the 
complementary mRNA, and to promote its endonucleolytic specific cleavage (Nykanen et al., 
2001; Tang, 2005). The target mRNA is cleaved at a single site in the centre of the duplex 
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region between the guide siRNA and the target mRNA, 10 nucleotides from the 5’ end of the 
siRNA (Elbashir et al., 2001b). 
 
 
 
Figure 7: The RNA interference pathway. Long double-stranded RNA (dsRNA) or small hairpin RNA 
(shRNA) are processed by Dicer to form a small interfering RNA (siRNA), which associates with RNA-induced 
silencing protein complex (RISC) and mediates target sequence specificity for subsequent mRNA cleavage (see 
text for further details, figure taken from nobelprize.org). 
 
 
2.3. RNAi in the brain 
 
RNAi is now widely used to explore the functions of genes in the nervous system of both 
invertebrates, such as C. elegans and Drosophila, and vertebrates (mammals, fishes…). 
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Experimental studies of RNAi against specific genes is also being exploited to understand the 
pathogenesis of neurological disorders and to develop novel therapeutic strategies for 
incurable diseases of the nervous system (Davidson and Paulson, 2004; Wood et al., 2003). 
Despite the ability of siRNA to reduce gene expression in mammalian neuron and glial cell 
cultures, we must recognize that the brain poses two problems with RNAi technique: the first 
is the restrictive passive entry of materials through BBB, thus rendering the systemic 
approach almost ineffective to generate siRNA-mediated gene knock-down in the brain. 
Secondly, a high degree of cellular diversity as well as networking adds to the complexity in 
achieving the desired gene knock-down within a specific type of cells in the brain.  
A critical goal for clinical neuroscience is the development of techniques with RNAi to 
understand the several activated pathways causing diseases and the development of effective 
therapies to prevent the neurological loss and suppressing the gene involved in 
neurodegeneration process that occurs in neurodegenerative diseases (Davidson and Paulson, 
2004; Thakker et al., 2006; Wood et al., 2003). 
 
 
2.4.  shRNAs 
 
In mammalian cells, a global response similar to an antiviral reaction was observed upon the 
introduction of long dsRNA into the cells (Elbashir et al., 2002). This mechanism is called the 
off-target effect. dsRNAs longer than 30 nucleotides trigger a dsRNA-mediated cell signaling 
pathway, including the induction of type I interferon synthesis and activation of interferon-
induced enzymes, such as dsRNA-dependent protein kinase and 2’, 5’-oligoadenylate 
synthetase. This global response results in nonspecific inhibition of gene expression, rather 
than specific knock-down of the targeted protein (Schiffelers et al., 2004). This obstacle has 
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been overcome by Elbashir and colleagues who found that gene-specific suppression in 
mammalian cells can be achieved by in vitro synthesized siRNA that are 19-22 nucleotides in 
length, long enough to induce gene-specific suppression, but short enough to avoid the host 
interferon response (Elbashir et al., 2001a). There are two different approaches to siRNA 
synthesis: exogenous chemical or enzymatic siRNA synthesis (Elbashir et al., 2001b). They 
observed a successful knock-down of exogenous gene expression (firefly luciferase expressed 
from plasmid), and endogenous gene expression (lamin A/C) in mammalian cell lines 
transfected with siRNA (Elbashir et al., 2001a). The second approach is an intracellular 
expression using plasmid or viral vectors producing short-hairpin RNAs (shRNAs) and 
achieve a transient or a permanent knock-down effect (McManus and Sharp, 2002; Tomar et 
al., 2003). shRNA is processed to siRNA through Dicer-mediated cleavage of the loop portion 
of the RNA hairpin (Paddison et al., 2002) and with the protein complex RISC allows the 
destruction of specific mRNA (for more details see section 2.). The design of shRNA is based 
on naturally occurring miRNAs and their sequence is composed of inverted repeat 19-29 
nucleotides with the desired sequence separated by a short loop of 6-9 base pairs (Figure 8) 
(Siolas et al., 2005). The design of shRNAs is primordial to obtain an efficient knock-down 
and no deleterious or unwanted effects in the cells. There are several web-based tools 
available for the design of effective siRNAs, based on various factors, like thermodynamic 
property, length of the shRNA target site (21 nt), GC content of the target site (range of 30-
60% as sequences with <60% GC content have a better chance to be functional shRNAs than 
those with higher GC content), sequence region (preferably 50-100 nt downstream of the 
“ATG” start codon), and control of off-target efficiency with BLAST search (Hajeri and 
Singh, 2009). 
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Figure 8: Different delivery system, plasmid or viral vectors, allow the transcription of shRNA in cells to 
achieve a knock-down effect (figure taken from www.genengnews.com). 
 
 
2.5. Viral vectors as tools for mediating RNAi  
 
In vivo use of siRNA to target CNS is difficult, due to the complexity of this organ, with its 
high degree of cellular diversity and to the tightness of BBB. Oral or intravenous 
administration of siRNA is not feasible because short nucleic acids do not cross BBB and are 
not efficiently internalized into target cells. Different methods were used like transfection of 
siRNA with lipidic reagents (Hassani et al., 2005), infusion aided by osmotic minipumps 
(Thakker et al., 2004), direct injection of siRNA into the brain parenchyma (Isacson et al., 
2003) including in combination with electroporation (Akaneya et al., 2005). However, the 
most promising method so far has been viral delivery of shRNAs (lentivirus, adenovirus, 
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adeno-associated virus or AAVs) due to the viral ability to transduce both dividing and non-
dividing cells (Flotte et al., 1994). AAVs have many advantages, including the lack of 
pathogenic and immunogenic effects, a long-term expression due to both persistent episomal 
status and their ability to integrate into the genome of transduced cells, as well as their 
capacity to transduce both dividing and non-dividing brain cells (Mah et al., 2002; Shi et al., 
2009; Stilwell and Samulski, 2003). AAV viral vectors are increasingly employed to develop 
experimental models of disease or in therapeutic purposes in clinical trials. It was shown that 
AAV-based delivery of shRNAs partially prevented the clinical, pathological and cytological 
aspects of the disease in a mouse model of spinocerebellar ataxia type 1 (Xia et al., 2004). 
 
 
2.6. Adeno-associated virus (AAV) 
 
AAV is a small, non-enveloped virus, member of the Parvoviridae family (genus 
Dependovirus), which is not associated with mammal or human diseases. In absence of a 
helper virus, like adenovirus, human cytomegalovirus or papillomavirus, AAV cannot 
replicate and establishes a latent infection within the cell, either by a site-specific integration 
into the host genome (in human, on chromosome 19, designated AAVS1) or by persisting as 
episomal forms (Buller et al., 1981). The virion shell is approximatively 25 nm in diameter 
and encapsidates a single-stranded DNA genome of 4.7 kb, converted into a double-stranded 
DNA after infection. Three functional regions are important in its genome: 2 large open 
reading frames (ORF), rep and cap, flanked by inverted terminal repeats (ITRs). The rep ORF 
encodes four replication proteins responsible for viral genome replication, transcriptional 
control, integration and encapsidation of AAV genome into capsid. The cap ORF encodes the 
viral structural proteins VP1, VP2, and VP3, allowing the formation of the icosahedral virion 
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shell. ITRs are the only cis-acting elements required for extrachromosomal replication and 
genomic integration of the transgene into the host cell genome (figure 9) (Wu et al., 2006). At 
least ten different AAV serotypes (AAV-1 to AAV-10) have been described, with different 
cell tropisms and antigenic properties (Cearley et al., 2008; Cearley and Wolfe, 2006; 
Zincarelli et al., 2008). A special feature of AAV is that its genome can be packaged into a 
capsid of its own serotype (isotype), or alternatively can be “cross-packaged” into capsid 
derived from another serotype (pseudotype). 
 
  
Figure 9: Representation of the adeno-associated-virus. A) Three-dimensional structure of the AAV capsid 
from VIPER database (http:// viperdb.scripps.edu). B) Schematic organization of the wild-type viral genome. 
 
 
AAV viral infection is a multistep process that requires virions to pass through a series of 
barriers: receptor binding, cell entry, intracellular trafficking, endosomal release, nuclear 
entry or viral uncoating. The cellular entry of non-enveloped viruses is often initiated by an 
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interaction of the capsid proteins and the cell surface glycosaminoglycan receptors. 
Subsequent secondary interaction of the viral capsid with coreceptors (fibroblast growth 
factor receptor 1, hepatocyte growth factor receptor and laminin receptor) appears to dictate 
the virus endocytosis and its intracellular trafficking pathway. The next step is the trafficking 
of AAV into the nucleus through a mechanism independent of the nuclear pore complex, the 
uncoating event taking place in nucleus (Wu et al., 2006). Inside the nucleus, the presence or 
absence of a helper virus dictates whether AAV enters a lytic or latent life cycle. In the 
absence of helper functions, AAV enters a latent cycle and integrates at a specific locus 
known as AAVS1 on chromosome 19 (in human) or persist in episomal form. The AAVS1 
sequence has been found only in humans and higher primates (McCarty et al., 2004). In 
contrast, in presence of a helper virus, induction of gene expression and replication take place 
immediately (Buning et al., 2008). 
The efficient transduction may involve cell entry process associated with receptor binding, 
internalisation and post-entry events such as cellular processing pathways, intracellular 
transport, or nuclear entry. 
For this study, we used recombinant AAV (rAAV) where all viral genes have been deleted, 
with only the two ITRs remaining. This vector has been used for delivery and expression of 
shRNA with enhanced safety and reduced immunogenicity.  
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III. Aims of the thesis 
 
 
To date no in vivo model of Cr deficiency syndrome show neurological symptoms and 
pathophysiology comparable with those found in Cr deficient patients. Their analysis on the 
neurological and behavioral points of view demonstrates only mild cognitive impairments, 
especially for the GAMT KO mouse. At the start of this work, the existing mouse KO models 
appeared inefficient to reproduce the neurological symptoms of Cr deficiency syndromes, and 
no study had been performed on the cellular and molecular perturbations observed in these 
diseases. We therefore chose to develop another, strategically new, experimental model of Cr 
deficiencies in 3D reaggregated brain cell cultures, which are are composed of all the types of 
brain cells, are organized in a 3D network resembling that of the in vivo brain, and therefore 
are considered as organotypic brain cell cultures (Honegger and Monnet-Tschudi, 2001). This 
model should allow to better understand the mechanisms at the cellular and molecular levels 
underlying the CNS pathology of creatine deficiency syndromes.  
 
The aim of this project was to develop new experimental models using RNAi in 3D 
reaggregated developing brain cell cultures to better understand the pathophysiology of Cr 
deficiency syndromes in the developing CNS. This project was divided in three parts: 
 
- In a first part, we developed new experimental models of Cr deficiencies in the 3D 
reaggregated brain cell cultures, by gene knockdown of GAMT and SLC6A8 genes 
using RNAi and a viral vector to transduce the cultures. 
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- In a second part, we validated this model by measuring the variation of proteins, 
mRNAs and metabolites that are characteristics of the Cr-deficient patients. 
 
 
- In a third part, we were interested in the consequences of the knockdown of GAMT or 
SLC6A8 genes on the integrity of the cultures and on the development of brain cells.  
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Chapter II: Materials and methods  
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I. Cloning 
 
 
1. Digestion with restriction endonucleases  
 
Plasmids containing the ORFs of GAMT and SLC6A8 or specific shRNAs were first digested 
with appropriate restriction endonucleases to remove the fragment of interest and to clone it in 
another plasmid. In parallel, the respective plasmids psiCHECK™-1 (for Dual-Luciferase  
Reporter assay system; Promega, Madison, WI, USA) or pAAV-hrGFP (for AAVs 
production; Agilent Technologies, Palo Alto, CA, USA) were digested with the appropriate 
restriction endonucleases to allow their linearization. Typically, 10 g of DNA was 
supplemented with 1 l of defined enzyme (Promega, Madison, WI, USA) and 1 l of 
enzyme buffer 10x in total volume of 10 l. The digestion mixture was placed in a water bath 
at a specific temperature (depending on the enzyme) for at least one hour. 
 
 
2. DNA gel electrophoresis 
 
The digestion products or PCR products were analysed by agarose gel electrophoresis to 
check the purity and size of digestion. Agarose at 1% (Roche Diagnostics Gmbh, 
Indianapolis, IN, USA) was dissolved in 200 ml TBE buffer 0.5X (Invitrogen, Carlsbad, CA, 
USA) in a microwave oven, then added with 20 l of Gel Red Nucleic acid stain (Biotium). 
The agarose gel was polymerized in the electrophoresis tray at room temperature (RT). Before 
loading the gel, 6x-loading dye (Promega, Madison, WI, USA) was added into the DNA 
samples and vortexed gently. The samples were loaded into wells and the gel was run in TBE 
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buffer 0.5x at 150-200 volts during approximately 2 hours. DNA bands were visualized by 
placing the gel on an UV-light Transilluminator ECX-26.M (Vilber Lourmat). 
 
 
3. DNA gel extraction 
 
Linearized plasmids and DNA fragments generated by restriction endonucleases digestion 
were excised from agarose gel under UV-light, using a scalpel blade and purified with Gel 
extraction kit (peqLAB, Germany), according to manufacturer’s instructions. 
 
 
4. Klenow enzyme 
 
When the termini of digested DNA fragments and vectors were not compatible for direct 
ligation, the large Klenow fragment of DNA Polymerase I was used to fill in 5’ or remove 
3’overhangs to form blunt ends. DNA was incubated with 25 units of Klenow large fragment 
(Promega, Madison, WI, USA), 1x Klenow buffer and 200 M of each dNTP (dATP, dGTP, 
dTTP, dCTP) in a total volume of 40 l, for 15 min at RT. The enzyme was inactivated at 
75°C for 10 min. 
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5. DNA dephosphorylation 
 
Dephosphorylation is a general process of removing phosphate monoester on the 5’ end of 
DNA provided by a specific enzyme, alkaline phosphatase. This process avoids the self-
ligation of DNA fragments or plasmids. According to manufacturer’s instructions, 5 g of 
DNA vector was supplemented with 1 unit of alkaline phosphatase and 1x enzyme buffer 
(Roche Diagnostics Gmbh, Indiapolis, IN, USA). The mixture was placed at 37°C during 20 
min and the enzyme was inactivated for 15 min at 75°C. 
 
 
6. DNA ligation 
 
DNA fragments were ligated into the linearized plasmid vector in the presence of 1x ligation 
buffer and 1 unit of T4 DNA ligase (Promega, Madison, WI, USA) in a total volume of 10 l. 
Several molar ratios were used during this study: 1:1, 1:3 and 3:1 (vector: insert). The ligation 
reaction was incubated overnight (O/N) at 16°C. 
 
 
7. Bacterial transformation 
 
The ligated plasmids were transformed into Subcloning efficiency DH5  competent cells 
(Invitrogen, Carlsbad, CA, USA). In a 15 ml tube, 5 l of the ligation reaction was incubated 
with 50 l of DH5  on ice for 30 min. The tube was placed for 30 seconds in water bath at 
42°C without shaking and then on ice for 2 minutes. The transformed bacteria were allowed 
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to propagate in 950 l SOC medium for 1 hour in a 37°C shaking incubator at 250 rpm. The 
tube was centrifugated for 2 min in a centrifuge at 1200 rpm. The bacteria pellet was then 
plated on LB agar plates supplemented with 100 g/ml of ampicillin (Applichem, Germany) 
and incubated O/N at 37°C. 
 
 
8. Screening of colonies 
 
On LB agar plates, few colonies were chosen to verify the cloning with restriction 
endonuclease digestion. For this, a colony picked with a sterile tip was added in a tube 
containing 5 ml of LB medium + Ampicillin (Applichem, Germany), and amplified by O/N 
incubation at 37°C in a shaking incubator (250rpm). The next day, the plasmid DNA was 
extracted by peqGOLD plasmid miniprep kit (peqLAB, Germany) (see below for explanation 
of method). To verify the insert of interest in the plasmid vector, several restriction 
endonuclease digestions were performed.  
 
 
9. DNA amplification 
 
Small- or large-scale preparations of DNA plasmids were performed using the mini- or 
maxiprep kits respectively (MP Biomedicals, France), according to manufacturer’s 
instructions. Briefly, the procedure consists of alkaline lysis of the bacterial cell membrane 
and RNA degradation with RNase buffer. After centrifugation, the supernatant containing 
nucleic acids is loaded in an anion-exchange resin column, on which the DNA is bound. 
Several wash steps are realized and DNA is eluted with elution buffer containing a low salt 
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concentration. For maxi-preps only, plasmid DNA was finally desalted by isopropanol 
precipitation followed by ethanol precipitation, and finally concentrated by resuspension in 
TE buffer or MilliQ H2O. The concentration of DNA elution was determined with the 
Nanodrop 2000c (Thermo Fisher Scientific Inc., Waltham, MA, USA). 
 
 
II. Polymerase chain reaction (PCR) 
 
 
Amplification of specific DNA fragments was performed by using the following PCR 
protocols. The PCR reaction mix was composed of 100 ng DNA, 40 ng primers (forward and 
reverse, Microsynth AG, Switzerland), 6 l MilliQ H2O and 12.5 l TaqPCR Mastermix (Taq 
DNA Polymerase, PCR buffer, 200 µM of each dNTP and 1,5 mM MgCl2; Qiagen, 
Germany) in a total volume of 25 l. Two different PCR programs were used with the 
GeneAmp PCR system 9700 (Applied Biosystem, Carlsbad, CA, USA): 
(i) Classic program with a first denaturation step at 94°C for 5 min; 40 cycles of denaturation 
(30 seconds, 94°C), annealing (30 seconds, temperature determined for each PCR depending 
of primers) and elongation (2 min, 72°C); and a final elongation step at 72°C for 5 min; final 
hold at 4°C. 
And (ii) program touchdown with first denaturation step at 95°C for 10 min; 35 cycles of 
denaturation (30 seconds, 95°C), annealing (30 seconds, 65°C to 55°C: temperature was 
decreased by 1°C for each of the first 10 cycles, and was kept constant at 55°C for the 
remaining cycles), and elongation (30 seconds, 72°C); and a final elongation step at 72°C for 
10 min; final hold at 4°C. 
PCR products were analysed by agarose gel electrophoresis, as described in section 1.2. 
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III. DNA sequencing 
 
 
The sequencing reaction mix was composed of 0.8 l purified PCR products, 0.8 l primer 
(50 ng/ l, forward or reverse; Microsynth AG, Switzerland), 0.8 l BigDye  Terminator 
V1.1, 0.4 l 5X buffer (Applied Biosystem, Carlsbad, CA, USA) and 2.2 l milliQ H2O in a 
total volume of 5 l. The plate was placed into a thermocycler GeneAmp PCR system 9700 
(Applied Biosystem, Carlsbad, CA, USA), and the sequencing process was composed of the 
following steps: a denaturation step at 96°C for 1 min; 25 cycles of denaturation (10 seconds, 
96°C), annealing (5 seconds, 50°C), and elongation (4 min, 60°C); followed by the final hold 
at 4°C for 7 min. 
The sequencing reaction was then purified with MontageTM SEQ96 Sequencing Reaction 
Cleanup Kit (for more details see manufacturer’s instructions ; Millipore Corporation, 
Billerica, MA, USA) and the purified reaction was placed into the 3100-Avant Genetic 
Analyzer (Applied Biosystem, Carlsbad, CA, USA). After the run, the sequence was analyzed 
with the program Sequencing Analyses version 3.7 (Applied Biosystem, Carlsbad, CA, USA). 
 
 
IV. Cell culture 
 
 
1. ROC, C6 and AAV-293 cells in monolayer cultures 
 
Three different cell lines were used: ROC cells (rat hybridoma between olidodendrocytes and 
astroglioma), C6 cells (derived from a rat astroglioma), and AAV-293 cells (derived from the 
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human embryonic kidney cell line HEK-293 and used to produce adeno-associated viruses). 
Cells were cultured under sterile conditions in DMEM (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% FBS (PAA laboratories GmbH, Pasching, Austria), 1% Penicillin-
Streptomycin (Invitrogen, Carlsbad, CA, USA) and 0.5% Hepes (Sigma-Aldrich, St-Louis, 
NO, USA; ROC and C6 only) in T75 culture flasks (Becton Dickinson Labware, England) at 
37°C, 5% CO2 in a humidified atmosphere. Cell splitting was performed at 90% confluence 
(ROC and C6) or 50% confluence (AAV-293) by removing culture medium, washing with 10 
ml of pre-warmed PBS, followed by 2 ml of 1% trypsin-EDTA (Invitrogen, Carlsbad, CA, 
USA) for 2 min. Trypsin activity was stopped by addition of 8 ml of fresh medium. 1 ml 
(1:10) of the cell suspension was then added into a new T75 culture flask previously filled 
with 10 ml of fresh DMEM. 
 
 
2. 3D primary brain cell cultures in aggregates 
 
3D primary brain cell cutures in aggregates were prepared from mechanically dissociated 
brains from 15-day old fetal rats (Sprague-Dawley, Harlan, Netherlands; animals handled 
according to the rules of the Swiss Academy for Medical Science, pregnant females and 
embryos killed by decapitation). These cultures were grown in a serum-free, chemically-
defined medium and cultured in flask under constant gyratory agitation as previously 
described (Honegger and Monnet-Tschudi, 2001; Braissant et al., 2002). These cultures 
develop with neurons, astrocytes, oligodendrocytes and microglia organized in a 3D network 
acquiring a tissue-specific pattern resembling that of the in vivo brain, and are therefore 
considered as organotypic brain cell cultures (Honegger and Monnet-Tschudi, 2001; Cagnon 
and Braissant, 2007). More specifically, these aggregates develop mature synapses, myelin 
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with fully formed nodes of Ranvier, spontaneous bioelectrical activity as well as biosynthesis, 
storage and release of neurotransmitters. We have shown that these cultures express AGAT, 
GAMT and SLC6A8 in the same cell types as the in vivo brain and synthesize their own Cr, 
suggesting that they behave as the in vivo CNS for Cr synthesis and transport (Braissant et al., 
2008; Braissant et al., 2001). Besides their histotypic cellular organization and maturation, 
these cultures offer the possibility to use multiple cultures replicates of high cell density, 
allowing a high reproducibility of experiments.  
 
 
2.1. Reagents for aggregate cultures 
 
DMEM powder without sodium pyruvate and sodium bicarbonate was purchased from 
Invitrogen (Carlsbad, CA, USA). Gentamicin sulfate, insulin, linoleic acid, α-tocopherol, 
3,3’,5-triiodo-L-thyronine, apo-transferrin, choline chloride, hydrocortisone 21-
hemisuccinate, alpha-lipoic acid and Basal Medium Eagle vitamin solution were purchased 
from Sigma (St Louis, MO, USA). Retinol, sodium bicarbonate, L-carnitine and vitamin B12 
were purchased from Fluka Chemie AG (Buchs, Switzerland).  
 
 
2.2. Culture of brain cell aggregates 
 
Embryos were removed from the uterus of pregnant rat females, and their whole brain was 
dissected out. Fetal brains were pooled in 50 ml of dissection medium (1g/L glucose, 20g/L 
sucrose, 25 mg/L Gentamicin sulfate, 160g/L NaCl, 8g/L KCl, and 0.9g/L Na2HPO4) and 
were dissociated mechanically, washed and resuspended in serum-free, chemically-defined 
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medium consisting of DMEM with high glucose (25mM) (Invitrogen, Carlsbad, CA, USA) 
supplemented with insulin (0.8 M), triiodo-L-thyronine (30 nM), vitamin B12 (1 M), L-
carnitine (10 M), choline chloride (2.5 g/l), lipoic acid (1 M), sodium chloride (3.7 g/l), 
hydrocortisone-21-phosphate (20 nM), transferrin (1 g/ml), linoleic acid (10 M), biotin (4 
M) and trace of vitamins (retinol, tocopherol) and ions (silicium, selenium, cadnium, cuivre, 
manganese, molybdene, nickel, etain, zinc). Gentamicin sulfate (25 g/ml) was used as an 
antibiotic. Cultures were incubated at 3.6 x 107 cells per flask in 8 ml culture medium and 
maintained under constant gyratory agitation at 37°C, in an atmosphere of 10% CO2 and 90% 
humidified air in a Hera Cell 240 incubator (Thermo Scientific). The rotary speed was 
progressively increased depending on the day of culture, DIV 0 (DIV: day in vitro; DIV 0 
being the day of dissection); DIV 0 end of dissection: 68 rpm; DIV 0 evening: 70 rpm; DIV 1 
morning: 74 rpm; DIV 1 evening: 77 rpm; DIV 4 morning and after: 80 rpm. 
 
Culture medium was removed every 3 days from DIV 5 onward by removing 5 ml of medium 
per flask and replenishing by 5 ml of fresh medium. Depending on experiments, aggregates 
were harvested at DIV 5, 6, 7, 8, 11, or 13.  They were then transferred in a 15 ml tube, 
pelleted and the medium was removed. Aggregates were washed three times with ice-cold 
PBS and either embedded in Tissue-Tek O.C.T. cryo medium (Digitina, Switzerland) for 
histology analysis, or frozen in liquid nitrogen for protein (Western-Blot), RNA (real-time 
quantitative PCR) or metabolite analysis. Samples were kept at -80°. 
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V. Techniques with shRNAs 
 
 
1. Dual-luciferase  reporter assay system 
 
Dual-luciferase  reporter assay system is a genetic reporter system which allows a 
quantitative and rapid approach for the optimization of RNAi site selection. The term « dual 
reporter » refers to the simultaneous expression and measurement of two individual reporter 
enzymes (Renilla and Firefly luciferases) within a single system. Typically, a target gene of 
interest is cloned in psiCHECK plasmid downstream of the stop codon for the Renilla 
luciferase gene, such that a hybrid mRNA is expressed (but not a hybrid protein). Initiation of 
RNAi toward the target gene results in the cleavage and subsequent degradation of the fusion 
mRNA including the Renilla luciferase coding sequence. This results in a decrease in Renilla 
luciferase activity that can be easily monitored as an indicator of the RNAi effect. The 
presence of a second reporter gene, Firefly luciferase, allows the normalization of transfection 
efficiency.  
 
During this work, the Dual-luciferase  reporter assay system was used to determine the 
efficiency of different GAMT and SLC6A8 shRNAs. 
 
 
2. Co-transfection of several plasmids 
 
To test the efficiency of each shRNAs, several co-transfections were performed with the 
jetPEITM (Polyplus transfection, Strasbourg, France) method. Briefly, jetPEITM compacts 
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DNA into positively charged particles capable of interacting with anionic proteoglycans at the 
cell surface and entering cells by endocytosis. For every condition, several plasmids were 
transfected into ROC cells: 
- psiCHECK in which our cDNA of interest has been cloned downstream of the Renilla 
luciferase coding sequence (1 g) 
- Plasmids expressing our shRNA sequence (0,5 g) 
- Control plasmid expressing the Firefly luciferase coding sequence (1 g) 
On the day of transfection, cells were plated in 12-well plates at a confluence of 50%. For 
each well, 50 l of NaCl 150 mM in which all 3 plasmids were diluted as well as a mix of 5 
l of jetPEITM and 50 l of NaCl 150 mM, were mixed together and incubated 30 min at RT. 
The DNA/jetPEITM solution was then distributed in each well and the 12-well plates were 
incubated at 37°C, 5% CO2 in a humidified atmosphere during 48 hours. After 6 hours, the 
transfection culture medium was removed and replaced by fresh DMEM. 
 
 
3. Measure of luciferases activites 
 
After 48 hours incubation time, cells were washed with phosphate buffered saline (PBS) and 
incubated at RT for 15 min on a rocking platform with 250 l of passive lysis buffer 
(Promega, Madison, WI, USA). 20 l of cell extract were added in a tube containing 50 l of 
Luciferase assay reagent II (Promega, Madison, WI, USA), and the tube was placed in the 
luminometer (TD-20/20, Turner Designs, Sunnyvale, CA, USA) to measure the activity of 
Firelfy luciferase. After the first measure, the tube was removed from the luminometer, and 
50 l of Stop and Glo reagent (Promega, Madison, WI, USA) was added. The tube was 
replaced in the luminometer and the Renilla luciferase activity was measured. Each condition 
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was performed in triplicate at least two times. The Renilla luciferase activity was divided by 
the Firefly luciferase activity in order to normalize for transfection efficiencies of cells, and 
multiplied by 100% to obtain efficiencies for each recording. 
 
 
4. Transfection of C6 or ROC cells with shRNAs 
 
To test the efficiency of each interferent or control shRNAs with an other method than the 
Dual-luciferase  reporter assay system, we analyzed the knock-down of the endogenous 
GAMT gene in C6 or ROC cells, by transfection with the jetPEITM method of plasmids 
expressing the shRNAs. The plasmid, expressing the sequence of each shRNA, expressed a 
resistance gene, the neomycin gene. The treatment of cells with the neomycin allowed to 
select the cells with a stable transfection. 
The day before transfection, C6 or ROC cells, expressing the GAMT gene, were plated in 6-
well plates at 150 000 cells per dish in 4 ml of DMEM culture medium supplemented with 
10% FBS and 1% Penicillin-Streptomycin (Invitrogen, Carlsbad, CA, USA).  The day of 
transfection, 3 g of plasmid were diluted in 100 l of NaCl 150 mM as well as a mix of 6 l 
of jetPEITM and 100 l of NaCl 150 mM, were mixed together and incubated 30 min at RT. 
The DNA/jetPEITM solution was then distributed in each well and the 6-well plates were 
incubated at 37°C, 5% CO2 in a humidified atmosphere. After 6 hours, the transfection culture 
medium was removed and replaced by fresh DMEM. After 24 hours, the cells were treated 
with 2000 g/ml of neomycin for the C6 cells and 300 g/ml for the ROC cells and, to select 
the cells expressing the plasmid. Then the cells were harvested after 6 days of transfection and 
the GAMT protein level was quantified by western blot. 
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VI. Techniques with adeno-associated-virus (AAV) 
 
 
The 3D primary brain cell culture in aggregates is a system with a high cellular complexicity, 
in which a transfection of shRNAs with phosphate calcium or polycationic reagent showed a 
low efficiency due to the presence of already post-mitotic cells. The AAVs serotype 2 and 5 
are known to efficiently transduce these types of brain cells. In this study, these AAV 2 and 5 
serotypes were used to transduce the best shRNA for our gene of interest in aggregates.  
The AAV Helper-Free System from Stratagene (Agilent Technologies, Santa Clara, CA, 
USA) allows the production of infectious AAV particles without the presence of helper 
adenovirus or herpes virus. This method is based on the co-transfection of several plasmids in 
AAV-293 host cells. The pHelper plasmid expresses the adenoviral E2A, E4, and VA genes; 
pAAV-RC expresses the AAV rep/cap-gene for AAV of serotype 2; pDP5rs expresses the 
AAV rep2/cap5-gene for AAV of serotype 5; pAAV-hrGFP contains the AAV inverted 
terminal repeats (ITRs) and the AAV-293 host cells stably express the adenovirus E1 gene, 
necessary to produce active viruses.  
To produce AAV serotype 2, pAAV-RC, pHelper and pAAV-hrGFP or recombinant pAAV-
hrGFP, in which our best shRNA and its promoter have been cloned, were required. For AAV 
serotype 2/5 it was pDP5rs, pHelper and pAAV-hrGFP or recombinant pAAV-hrGFP, in 
which our best shRNA and its promoter have been cloned. 
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1. AAVs production 
 
The plasmids pHelper, pAAV-RC and pAAV-hrGFP were purchased from Stratagene 
(Agilent Technologies, Santa Clara, CA, USA); pRep2/5 was purchased from Aldevron 
(Fargo, ND, USA). 
 
In this study, the following AAVs were produced by co-transfecting the following respective 
plasmids in AAV-293 cells: 
1. AAV2-control  pHelper + pAAV-RC + pAAV-hrGFP 
2. AAV2-shRNA GAMT  pHelper + pAAV-RC + pAAV-hrGFP in which shRNA for 
GAMT gene has been cloned (pAAV-shRNA GAMT) 
3. AAV2-shRNA SLC6A8  pHelper + pAAV-RC + pAAV-hrGFP in which shRNA for 
SLC6A8 gene has been cloned (pAAV-shRNA SLC6A8) 
4. AAV2/5-control  pHelper + pRep2/5 + pAAV-hrGFP 
5. AAV2/5-shRNA GAMT  pHelper + pRep2/5 + pAAV-shRNA GAMT 
6. AAV2/5-shRNA SLC6A8  pHelper + pRep2/5 + pAAV-shRNA SLC6A8 
 
48 hours before transfection, AAV-293 cells were plated at 2x106 cells per 100 mm diameter 
culture dish in 10 ml of DMEM culture medium supplemented with 10% FBS and 1% 
Penicillin-Streptomycin (Invitrogen, Carlsbad, CA, USA). Each AAV production necessitated 
the culture of 11 dishes. 
On the day of transfection, cells were approximately 70-80% confluent to allow an efficient 
AAV production. Into a 15 ml conical tube containing 11 ml of 0.3M CaCl2 (Invitrogen, 
Carlsbad, CA, USA), 110 g of each of the three plasmid DNA solutions were added and the 
solution was mixed gently by inversion. This DNA/CaCl2 mixture was added in a dropwise 
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fashion in a second tube containing 11 ml of 2x HBS (Invitrogen, Carlsbad, CA, USA). The 
transfection mixture was mixed by inversion and 2 ml/plate were immediately applied on 
cells. The dishes were swirled gently to distribute the DNA suspension evenly in the medium 
and were placed in a 37°C incubator for 6 hours. At the end of the incubation time, the 
medium was removed and replaced with 10 ml of fresh DMEM medium complemented with 
10% FBS and 1% Penicillin-Streptomycin (Invitrogen, Carlsbad, CA, USA). The dishes were 
returned in the 37°C incubator for 72 hours. 
Three days after transfection, the cells and the medium were collected into a tube and four 
rounds of freeze/thaw were performed by alterning the tubes between dry-ice and a 37°C 
water bath. Each round was of 10 min. The supernatant containing the viral particles was 
transferred into a tube after a 10,000 x g centrifugation for 10 min at RT. The viral stock was 
stored at -80°C before purification.  
 
 
2. AAVs purification 
 
Before purification, the viral stock was treated with 0.1 l / ml Benzonase  (Roche) for 1 
hour at 37°C in water bath. This treatment allows to remove much of the contaminating 
DNAs or RNAs (simple or double stranded, linear or circular).  
The AAV Purification VirakitTM (Virapur, San Diego, CA, USA; for more details see the 
manufacturer’s intructions) was used for purification of AAV serotype 2 and 5. Briefly, the 
viral suspension was purified by passing it through a 0.45 m filter. After adding a dilution 
buffer, the virus solution was slowly passed over a treated filter, which absorbs the viral 
particles, allowing much of cellular debris to pass through the filter. The washing buffer was 
passed over the column to remove any bound debris, and the virus was eluted off the filter 
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with elution buffer. The viral stock was stored at -20°C until the utilisation in several cell 
cultures (ROC, C6, aggregates). 
 
 
3. AAVs titration 
 
AAV particles in purified viral stocks were quantified with an enzyme immunoassay, AAV2 
or 5 Titration ELISA (Progen Biotechnik GMBH, Heidelberg, Germany). The assay is based 
on the sandwich ELISA technique. A monoclonal antibody specific for a conformational 
epitope on assembled AAV2 or AAV5 capsid was coated onto microtiter strips in 96 well 
plates and was used to capture AAV2 or AAV5 particles from the samples. Captured AAV 
particles were detected in two steps. First a biotin-conjugated monoclonal antibody to AAV2 
or AAV5 was bound to the immune complex. In the second step streptavidin peroxidase 
conjugate was reacted with the biotin molecules. Addition of substrate solution resulted in a 
color reaction which was proportional to the amount of specifically bound viral particles. The 
absorbance was measured photometrically at 450 nm (see manufacturer’s intruction). Briefly, 
100 l of the serial dilutions of kit control (empty AAV capsids for titration curve) and 
samples were added into the wells of the microtiter strips for 1 hour at 37°C in an incubator. 
After 3 washing steps with 200 l of washing buffer, all wells were complemented with 100 
l of biotin conjugate for 1 hour at 37°C. After 3 washing steps with 200 l of washing 
buffer, 100 l of streptavidin was added into the wells for 1 hour at 37°C. After the last 
washing step, 100 l of substrate were added into the wells for 10 min at RT and the reaction 
was stopped with 100 l of stop solution. Intensity of color reaction was measured with a 
Nanodrop 2000c (Thermo Fisher Scientific Inc., Waltham, MA, USA) at 450 nm. 
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VII. Techniques with RNA 
 
 
1. RNA extraction 
 
RNA extraction was performed on aggregated brain cells harvested at day 5, 6, 7, 8 or 11 and 
preserved at -80°C with AllPrep DNA/RNA/Protein Mini Kit (Qiagen, Germany). According 
to manufacturer’s protocol, the cells were first lysed and homogenized in Buffer RLT, which 
inactivated RNases to ensure isolation of intact RNA. The lysate was then passed through an 
AllPrep DNA spin column. After centrifuge, ethanol was added to the flow-through of 
AllPrep DNA spin column to provide appropriate binding conditions for RNA, and the 
sample was applied to an RNeasy spin column, where total RNA was binded to the 
membrane, which contaminants were washed away. RNA was then eluted in RNase-free 
water. The concentration of the total RNA was measured with the Nanodrop 2000c (Thermo 
Fisher Scientific Inc., Waltham, MA, USA). 
 
 
2. Reverse transcription reaction  
 
The mRNAs extracted as above were transcribed by reverse transcription into complementary 
DNA (cDNA) strand by using poly-dT oligonucleotide primer hybridizing on the poly-A tail 
of the mature mRNA, and random 6-mers primers setting anywhere on the RNA. Reverse 
transcription reaction was performed with PrimeScriptTM RT kit (Takara Bio Inc., Japan) with 
the following conditions: the reaction mix was composed of 2 g total RNA, 4 l 5 x Prime 
Script buffer, 1 l Prime Script RT enzyme, 1 l oligo-dT primers (50 µM), 4 l 6-mers 
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random (100 µM) in a total volume of 20 l. The tubes were placed into a thermocycler 
GeneAmp PCR system 9700 (Applied Biosystem, Carlsbad, CA, USA) and the program was 
composed of two steps: reverse transcription for 15 min at 37°C and inactivation of enzyme 
for 5 secondes at 95°C. RT products were stored at -20°C before performing real time 
quantitative PCR. 
 
 
3. Real-time quantitative PCR (qPCR) 
 
The real-time PCR is used to amplify and simultaneously quantify a targeted DNA molecule. 
The procedure follows the general principle of polymerase chain reaction; its key feature is 
that the amplified DNA is detected as the reaction progresses in real time, a new approach 
compared to standard PCR, where the product of the reaction is detected at its end. In this 
study, we have used the methods with non-specific fluorescent dyes that intercalate with any 
double-stranded DNA. 
Before starting the qPCR, cDNA samples were diluted to 50 ng with RNase free water, and 
one sample was diluted at different concentrations (100 ng, 50 ng, 25 ng, 12.5 ng) to form the 
standard curve. The qPCR reaction mix is composed 1 l of diluted cDNA, 10 M of each 
forward and reverse primers, 12.5 l of ABsolute QPCR SYBR Green Mix 2x (Thermo 
Fisher Scientific Inc., Waltham, MA, USA) and 10.5 l RNase free water in a total volume of 
25 l. Samples were placed into a thermocycler Rotor-Gene 6000 (Qiagen, Germany) and run 
with the following steps: enzyme activation at 95°C for 15 min; 40 cycles of denaturation (15 
secondes, 95°C), annealing (30 seconds, 50-60°C), and elongation (30 seconds, 72°C). After 
the run, the results were analysed with the Corbett Rotor-Gene 6000 Application Software, 
version 1.7 (Qiagen, Germany). 
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VIII. Western blot analysis of proteins 
 
 
During this work, the expression of several specific proteins were analyzed by western 
blotting, making use of the following specific primary antibodies (table n°1) and specific 
secondary antibodies (table n°2). 
 
Table 1: List of the proteins (antigens) analyzed in this work, and their specific 
antibodies used for western blotting analysis. 
 
ANTIGEN DILUTION 
MOLECULAR 
WEIGHT 
SPECIES SUPPLIER 
SLC6A8 1 :500 61 kDa rabbit 
Homemade 
Braissant et al., 
2005 
GAMT 1 :500 26 kDa rabbit 
Homemade 
Braissant et al., 
2005 
α - tubulin 1 :1000 55 kDa rabbit Santa Cruz  
Caspase 3 1:1000 
Full 35kDa 
Cleaved 17 kDa 
rabbit Cell Signaling 
Phospho p38 
MAPK 
1:1000 43 kDa rabbit Cell Signaling 
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Table 2: List of secondary antibodies used in this study 
 
Conjugation Dilution Species Supplier 
HRP-conjugated IgG 1 :3000 Goat anti-rabbit BioRad 
HRP-conjugated IgG 1 :3000 Goat anti-mouse BioRad 
HRP-conjugated IgG 1 :3000 Donkey anti-goat Santa Cruz 
 
 
1. Preparation of samples 
 
Once harvested, cell samples were homogenized in lysis buffer containing 8M urea, 25mM 
Tris-HCl pH8, 1% SDS and Protease inhibitor Complete (Roche, Switzerland), and sonicated 
for 5 secondes. Homogenates were centrifuged at 12,000 x g for 10 min at 4°C in a 
microcentrifuge, and supernatants were recovered. Supernatant proteins were quantified by 
the bicinchoninic acid BCATM Protein assay (Pierce, RockfordIL, USA). All samples were 
diluted at the same concentration in NuPage  sample buffer containing 0,14 M Tris Base, 0,5 
mM EDTA, 10% glycerol, 2% lithium dodecyl sulphate, 500 mM dithiothreitol (Invitrogen, 
Carlsbad, CA, USA) and heated at 70°C for 10 minutes (denaturation of protein by heat). 
 
 
2. SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Polyacrylamide NuPage 12% Bis-Tris gels (Invitrogen, Carlsbad, CA, USA) were used to 
separate the proteins of interest according to their molecular weight. The migration was 
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performed in 3-N-morpholino-propanesulfonic acid or MOPS running buffer containing 50 
mM of MOPS, 50 mM Tris Base, 0.1% sodium dodecyl sulphate (SDS), 1 mM EDTA 
(Invitrogen, Carlsbad, CA, USA), at a constant voltage (200V) during 58 minutes.  
 
 
3. Immunoblotting 
 
After electrophoresis, polyacrylamide gel and Whatman filter papers were placed in Bjerrum 
buffer (48mM Trizma Base, 39 mM Glycine, 0,13 mM SDS, 15% methanol) for a few 
minutes under agitation. A « sandwich » was performed in the Transblot SD semi-dry transfer 
cell (Biorad, Hercules, CA, USA) with Whatman filter papers, an Immobilon polyvinylidene 
difluoride (PVDF) membranes (Millipore, Bedford, MA, USA), and the polyacrylamide gel. 
Protein samples were transferred from gel to the PVDF membrane under an electric current of 
13V during 70 minutes.  
After tansfer, PVDF membranes were washed 2 x 10 minutes with TBS-Tween (20 mM 
Trizma Base pH 7.5, 137 mM NaCl, 0,05% Tween 20), and then blocked with 5% non-fat dry 
milk in TBS-Tween for 2 hours at room temperature (RT) to avoid unspecific binding of the 
antibody. After blocking, PVDF membranes were incubated overnight (O/N) with primary 
antibodies diluted in 3% dry milk and TBS-Tween. The respective dilutions of primary 
antibodies used in this work are listed in table 1. On next day, PVDF membranes were 
washed 3 x 10 minutes with TBS-Tween and incubated with horseradish peroxydase (HRP)-
coupled goat anti-rabbit IgG or goat anti-mouse IgG (1:3000; Vector laboratories, 
Burlingame, CA, USA; table 2). A final wash of membranes was performed during 2 hours 
with TBS-Tween and Amersham ECL™ Western Blotting Detection Reagents (Amersham 
Biosciences, Buckinghamshire, UK) were applied on the PVDF membranes to allow signal 
  
 
59 
revelation by chemiluminescence (Kodak M35 X-OMAT Processor). Blots could be stripped 
with Re-Blot Plus Mild antibody stripping solution (Chemicon, Temecula, CA, USA) and 
reprobed with other antibodies. The autoradiograms were scanned with an ImageScanner 
(Amersham Biosciences, Buckinghamshire, UK) and analyzed with the ImageJ image-
processing program. Data were acquired in arbitrary densitometric units and transformed to 
percentages of controls. 
 
 
IX. Immunohistochemistry 
 
 
Immunohistochemistry was used to follow the expression of specific cell type markers in 
brain cell aggregates and analyze the morphology of brain cells.  
 
1. Antibodies 
 
The following antibodies were used for immunohistochemistry during this work (tables 3, 4). 
 
Table 3: List of primary antibodies used in this work 
 
Antigen Dilution Species Supplier 
GFAP 1 :100 mouse Millipore 
pNFM 1 :100 mouse Sigma 
MBP 1 :100 goat Santa Cruz 
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Table 4: List of secondary antibodies used in this work 
 
Conjugation Dilution Species Supplier 
HRP-conjugated IgG 1 :200 Goat anti-mouse BioRad 
HRP-conjugated IgG 1 :100 Rabbit anti-goat Dako Cytomation 
 
 
2. Method 
 
16 m-thick cryosections of aggregate pellets were performed on a CM1850 UV cryostat 
(Leica) and fixed by incubation in 4% paraformaldehyde for 1 hour at RT. After 3 washing 
steps with PBS 1x for 5 min at RT, sections were incubated in 1% H2O2 (TraceSelect 30%, 
Fluka Chemie AG, Buchs, Switzerland) for 15 min at RT to quench peroxidase activity. The 
non-specific antibody binding sites were blocked by incubation in 1% BSA (Sigma-Aldrich, 
St-Louis, NO, USA) for 15 min at RT. The primary antibody diluted in appropriate 
concentration in 1% BSA was applied on slide for 2 hours at RT, excepted for the anti-MBP 
antibody which was incubated O/N at 4°C. After 3 washing steps with 1x PBS for 5 min at 
RT, the HRP-coupled secondary antibody diluted in 1x PBS was added for 1 hour. Peroxidase 
staining was performed using 3-Amino-9-Ethylcarbazole or AEC Substrate Set (BD 
Biosciences, San Diego, CA, USA) and the reaction was stopped by immersing the slides in 
H2O. For all experiments, the negative control was performed with no primary antibody 
incubation. Sections were mounted under FluorSave™ Reagent (Calbiochem, San Diego, CA, 
USA). 
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Slides were observed by the use of an Olympus BX50 microscope and photos were taken with 
an Olympus Color View 2 camera. Images were analyzed using image-processing software 
(Cell Imaging Software, Olympus). 
 
 
X. In situ cell death detection 
 
 
The cleavage of genomic DNA in cell generated by  apoptosis can be detected and quantified 
with the method of terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end 
labeling or TUNEL. This staining was performed on cryosections (16 µm) of aggregates, 
according to supplier recommandations using In Situ Cell Death detection kit Fluorescein 
(Roche Diagnostics, Switzerland). Briefly, sections were fixed by incubation in 4% 
paraformaldehyde for 20 min at RT. After 3 washing steps with PBS 1x for 30 min at RT, 
sections were permeabilized 2 min with 0.1% Triton X-100, 0.1% sodium citrate at 2-8°C. 
After 3 washing steps with PBS 1x, sections were incubated with a mix of TdT from calf 
thymus and fluorescein-dUTP for 1 hour at 37°C in humid chamber. Slides were observed 
under microscopy with a specific filter of fluorescence (excitation at 450-500 nm; emission at 
515-565 nm), resulting in green fluorescence within apopototic cells. For negative control, 
TdT was omitted resulting in no nuclear staining. 
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XI. Measure of extracellular GAA and Cr by tandem 
mass spectrometry 
 
 
Brain cell aggregates were homogenized in H2O at 4°C using a FastPrep Cell Disrupter 
(Qbiogene, France) and centrifuged at 10 000g during 5 min at 4°C. Creatine and 
guanidinoacetic acid determinations in the cell supernatants were performed by electrospray 
tandem mass spectrometry. 15 l d3-creatine and 
13C2-Guanidinoacetic acid each at 10 M 
(CDN Isotopes Inc, Quebec Canada), 4 l formic acid was added to 600 l of cell 
supernatant. The analytes were purified by micro solid phase extraction ( -SPE) using the 
Oasis MCX Elution Plate (Waters, MA USA). The procedure comprised of what is typical 
for SPE, conditioning of the -SPE wells by methanol (MeOH), application of the diluted 
samples, wash steps by 2 % (v/v) formic acid and MeOH and final elution with 5 % (v/v) 
NH4OH in H2O. 
Chromatographic analysis was performed using a Rheos CPS-LC (Flux Instruments, 
Switzerland) and a PAL SYSTEM autosampler (CTC Analysis, Switzerland). 
Separation of the analytes was achieved at 30 °C using an Atlantis HILIC silica 2.1 x 50 mm 
(Waters, MA USA). The mobile phases used for the chromatographic separation were 
composed of 20 mM ammonium formate, 0.4 % (v/v) formic acid in H2O and acetonitrile. 
The column effluent was monitored using a Triple Quadrupole TSQ Quantum Discovery 
(Thermo Scientific, CA USA). The instrument was equiped with an electrospray interface and 
was controlled by the Xcalibur software (Thermo Scientific, CA USA). The sample were 
analyzed in the positive ionization mode operating in a cone voltage of 4 kV. The tandem 
mass spectrometer was programmed using the selected reaction monitoring mode (SRM) to 
allow the [MH+] ions of creatine at m/z 132.1 and that of guanidinoacetic acid at m/z 118.1 to 
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pass through the first quadrupole (Q1) and into the collision cell (Q2). The daughter ions for 
creatine and guanidinoacetic acid were of m/z 90.1 and 76 respectively. Calibration curves 
were computed using the ratio of the peak area of the analytes and internal standard using a 
weighted (1/x2) least squares linear-regression analysis. 
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Part I: Study of GAMT deficiency syndrome 
 
 
I. Knockdown of GAMT expression 
 
 
The open reading frame of the GAMT gene is composed of 711 nucleotides and located on 
chromosome 19 (19p13.3) in human (Almeida et al., 2007) and on chromosome 7 (7q11) in 
Rattus norvegicus. The protein encoded by this gene is a methyltransferase that converts 
guanidinoacetate to creatine, using S-adenosylmethionine as the methyl donor. Mutations in 
this gene are implicated in the first described of the three Cr deficiency syndromes, GAMT 
deficiency (Stöckler et al., 1994). In these syndromes, 
 
To study the consequences of GAMT deficiency in developing brain cells, our aim was to 
develop an experimental model in vitro of GAMT deficiency syndrome by using the 
technique of RNA interference. 
 
 
1. Choice of the best interfering sequences 
 
In order to generate a new experimental model of GAMT deficiency by RNA interference, we 
have designed several shRNA sequences with the Genscript’s software incorporating several 
different rules such as thermodynamic property, length of the shRNA target site (21 nt), GC 
content of the target site (range of 30-60%, as sequences with < 60% GC content have a better 
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chance to be functional shRNAs than those with higher GC content), sequence region 
(preferably 50–100 nt downstream of the "ATG" start codon), and control of off-target 
efficiency with BLAST search. 
Each shRNA was composed by 21 nt of the antisense (reverse complement) GAMT coding 
sequence, followed by a hairpin sequence and the corresponding sense 21 nt of the GAMT 
coding sequence. For shRNA 1, 2 and 3, the coding sequence represented nucleotides 309-
329, 576-596, and 467-487, respectively, downstream from the start codon of the rat GAMT 
ORF (GenBank accession no. NM_012793) (figure 10). 
 
 
Figure 10: Sequences of each selectioned shRNA and their respective position on GAMT ORF.  
 
 
The 3 shRNAs selectioned were inserted as DNA into the pRNAT-CMV3.2/Neo vector 
between the restriction sites BamHI and XhoI. In this vector, CMV promoter drives the 
expression of shRNA, and SV40 promoter drives the expression of the neomycin gene, a 
resistance gene, and cGFP (coral GFP) for tracking the transfection efficiency (see below 
figure 11). 
 
siRNA-GAMT 1: GGATCCTCGTTGCATTCAATAATCCAGTTGATATCCGCTGGATTATTGAATGCAACGACGCTCGAG
siRNA-GAMT 2: GGATCCTACTTGGACTTCATGAGTTCCTTGATATCCGGGAACTCATGAAGTCCAAGTACGCTCGAG
GGATCCTGTGCCAGGTCTCTTCAGACATTGATATCCGGGAACTCATGAAGTCCAAGTACGCTCGAGsiRNA-GAMT 3:
Antisense Loop SenseBamH I Xho I
GAMT ORF, 711 nt
1 3 2
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Figure 11: Circle map of pRNAT-CMV3.2/Neo (figure taken from www.genscript.com). 
 
 
1.1. Dual-luciferase  reporter assay system 
 
The goal of the first part of the study was to determine the efficiency of each shRNA on the 
GAMT expression in monolayer cell cultures. For this, we used the Dual-luciferase  reporter 
assay system which is a quantitative and rapid approach for the optimization of RNAi 
selection (for more explanation see chapter II). Briefly, the ORF of GAMT was cloned into 
the psiCHECKTM plasmid downstream of the Renilla luciferase gene, allowing the 
transcription of a hybrid mRNA. If the GAMT shRNA is not efficient, the traduction of the 
hybrid mRNA containing the Renilla luciferase and the GAMT ORF can occur and the 
bioluminescence activity emitted by the Renilla luciferase protein can be monitored. On the 
other side, if the GAMT shRNA is efficient to knockdown GAMT, the cleavage and the 
degradation of the hybrid mRNA containing the Renilla luciferase and the GAMT ORF is 
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initiated, and therefore no activity of Renilla luciferase can be monitored. The decrease in 
Renilla luciferase activity is a good indicator for the RNAi efficiency (figure 12). 
 
 
Figure 12: Schematic outline of the Dual-luciferase  reporter assay system. A) Vector expressing the 
Renilla luciferase gene fused to GAMT ORF. B) To determine the efficiency of different shRNAs, the plasmid 
expressing Renilla luciferase and GAMT ORF is co-transfected with the plasmid expressing shRNAs in cell 
culture. C) shRNA is not efficient to knockdown the target mRNA sequence, and the Renilla luciferase protein is 
translated and high luciferase activity is recorded. D) shRNA is very efficient to knockdown the target mRNA 
sequence, and high level of degradation of the fusion mRNA leads to low or no luciferase activity. 
 
 
1.1.1. Clonage of GAMT ORF in the psiCHECKTM vector 
 
The ORF of GAMT was excised from the pBS-KS- vector by digestion with Xho I and Sma I, 
purified by agarose gel electrophoresis and ligated into the psiCHECKTM vector, pre-digested 
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with Xho I and Sma I (figure 13). To determine the presence of our insert into the plasmid, we 
screened the colonies obtained after transformation of DH5α bacteria with 2 restriction 
enzymes, BamH I and Pst I. The expected result of this digestion was 3 bands with different 
molecular weight: 2284 bp, 1279 bp, and 648 bp. The cloned product was amplified by 
maxiprep and sequenced with two primers (forward: 5’- CAG CCA GGA GGA CGC TCC 
AG -3’; reverse: 5’- GCC ACC TGG ATC CTC ACA C -3’) to ensure that no mutations had 
been introduced in the GAMT ORF. 
 
 
 
Figure 13: Schematic outline of the clonage of GAMT ORF in psiCHECKTM vector. The pBluescript KS- 
vector containing the GAMT ORF was digested by two restriction enzymes, SmaI and XhoI, to excise the 
fragment of interest. After the digestion of psiCHECKTM vector by SmaI and Xho I, the GAMT ORF was ligated 
into the psiCHECKTM vector. The expression of the hybrid mRNA (Renilla luciferase and GAMT ORF) was 
driven by the T7 promoter. hRLuc, Renilla luciferase ; Amp R, Ampicillin resistance gene ; pUC ori, pUC origin 
of replication sequence. 
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1.1.2. Determination of RNAi efficacy in ROC cells 
 
The quantitative assessment of shRNA efficiency was analyzed as follows 24 hours after 
seeding in 12 well plates. Rat oligodendroglia-C6 astroglioma hybridoma cells (or ROC cells) 
were transfected with three differents plasmids, the reporter psiCHECKTM containing the 
GAMT ORF, the Genscript plasmid expressing the GAMT shRNA, and p-Firefly as 
transfection control. A shRNA for synaptotagmin 4 gene, as well as the psiCHECKTM vector 
containing the synaptotagmin 4 ORF, were used as positive control. The luciferase activity 
was recorded 48 hours after transfection. As shown in figure 14, shRNAs 2 and 3 
significantly down-regulated the expression of the luciferase, with a decrease of 
approximatively 80% of luciferase activity for the GAMT-2 shRNA (figure 14). 
 
 
Figure 14: Silencing of luciferase activity by different shRNAs specific for GAMT ORFs, and 
Synaptotagmin 4 (SYT4) as positive control. ROC cells were transfected with a plasmid expressing firefly 
luciferase as a reporter for normalization of transfection, a psiCHECKTM vector expressing GAMT open reading 
frame (or SYT4 open reading frame) downstream of the Renilla luciferase open reading frame, and plasmids 
expressing shRNAs specific for GAMT or SYT4. Luciferase activity is shown on the Y axis in arbitrary units 
(controls for SYT4 and GAMT: 100%). Mean  SD (n=8; NS: non-significative; ***: p<0.001).  
 
 
 
 
psiCHECK SYT4 +
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*** *** ***
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Our results based on the luciferase activity test suggested that the GAMT-2 shRNA had the best 
efficiency to knock down the expression of GAMT mRNA. 
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1.2. Off-target effect 
 
In the first part of the study, we have demonstrated, by the technique of Dual-luciferase  
reporter assay system, that the GAMT-2 shRNA had the best potential to knock-down the 
GAMT gene. Several studies have reported that the siRNA-mediated gene silencing could be 
less specific than originally thought (Jackson et al., 2006). The interpretation of data from 
RNA interference has become complicated due to unintended interactions between the siRNA 
and non specific cellular components, the so-called off-target effects (Echeverri and Perrimon, 
2006). Briefly off-target effects include the induction of the antiviral interferon pathway 
machinery, the insertion of the sense siRNA into the RISC complex instead of the antisense 
strand or the nucleotide sequence similarity between the siRNA molecule and short motifs in 
mRNAs of other genes not intended to be knocked-down (Jackson et al., 2003; Tschuch et al., 
2008). To avoid these off-target effects on our results, we have designed two supplementary 
negative controls in the form of mismatched and scrambled sequences. The mismatched 
sequence had the same sequence than GAMT-2 shRNA except 4 mutated bases, while the 
scrambled sequence had the same composition of bases than GAMT-2 shRNA but in a 
different randomized order (figure 15). 
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Figure 15: Schematic representation of GAMT-2 A), mismatched B) and scrambled C) GAMT shRNA 
sequences cloned into pRNAT-CMV3.2/Neo vector. 
 
 
These sequences were inserted into pRNAT-CMV3.2/Neo vector between the restriction site 
BamHI and XhoI (figure 11). This vector expresses cGFP and a resistance gene under the 
control of SV40 promoter. This gene allows the selection of transfected cells with an 
antibiotic, the neomycin.  
To demonstrate that these sequences have no effects on GAMT gene expression, we have 
transfected rat astroglioma C6 cells cells which do express the GAMT gene with the plasmid 
vectors expressing mismatched or scrambled GAMT-shRNA sequences. In parallel, in order 
to confirm the results obtained with the Dual-luciferase  reporter assay system, we quantified 
the expression of the GAMT protein in the presence of GAMT-2 shRNAs. Briefly, the cells 
were plated in 6 well plates at 150 000 cells/dish. The next day, the cells were transfected 
with plasmids expressing the mismatched GAMT-shRNA or the scrambled GAMT-shRNA, 
and the GAMT-2 shRNA. 24 hours after transfection, the cells were treated with 2000 µg/ml 
of neomycin to select the transfected cells. One week after the transfection, the cells were 
harvested and the protein were extracted to realize western blot and to quantify the GAMT 
GGATCCTACTTGGACTGGATGAGTTCCTTGATATCCGGGAACTCATCCAGTCCAAGTACGCTCGAG
BamH I Xho ISenseAntisense Loop
B.
C.
GGATCCACCTAATTGCGTAAGGAGAACTTGATATCCGGTTCTCCTTACGCAATTAGGTCGCTCGAG
BamH I Xho ISenseAntisense Loop
GGATCCTACTTGGACTTCATGAGTTCCTTGATATCCGGGAACTCATGAAGTCCAAGTACGCTCGAG
BamH I Xho ISenseAntisense Loop
A.
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protein. Our preliminary results show that the GAMT protein level is not decreased under 
mismatched or scrambled shRNAs as compared to the empty vector, while GAMT-2 shRNA 
induced pronounced decrease of the GAMT protein (figure 16). However, work is still going 
on to better document the absence of off-target effects of GAMT RNAi. 
 
 
 
Figure 16: GAMT protein expression level after transfection with plasmids expressing GAMT-2, 
mismatched or scrambled shRNAs in ROC cells. The cells were harvested 120 hours after the transfection 
with the plasmids expressing shRNA GAMT-2, shRNA mismatched, shRNA scrambled or not (Empty). Western 
blot showing the GAMT protein level from control cells, or cells transfected with plamids Empty or expressing 
GAMT-2 shRNA or mismatched and scrambled shRNA for GAMT-2. 
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These preliminary results show that both mismatched and scrambled sequences for GAMT-2 
shRNA have not effect on the GAMT protein level, suggesting that the GAMT-2 shRNA is 
efficient to down-regulate the GAMT gene in C6 cells. 
  
 
75 
II. The experimental model of GAMT deficiency 
syndrome in 3D reaggregated brain cell cultures 
 
 
After having selected the best GAMT shRNA interfering sequence in monolayer cell cultures, 
our aim was to develop a new experimental model of GAMT deficiency in the organotypic in 
vitro system of 3D reaggregated brain cell cultures. Due to the 3D complexity of brain cell 
aggregates, and to the fact that most of the cells are already post-mitotic at the start of the 
culture, classical transfection protocols (e.g. JetPEI or CaPO4) could not be used. Viral 
vectors appear as an efficient tool for gene transfer into brain cells, essentially due to their 
ability to transduce both dividing and non-dividing cells. We have decided to use AAV 
viruses as vectors to transduce the best GAMT shRNA into 3D reaggregated brain cell 
cultures, as AAVs are known to transduce all type of brain cells, whichever they are mitotic 
or not.  
 
 
1. Construction of AAV vectors 
 
The vector containing GAMT-2 shRNA sequence was digested by two restriction enzymes, 
BglII and XbaI, to remove the CMV promoter and the shRNA sequence. This fragment was 
purified by agarose gel electrophoresis and ligated in the pAAV-hrGFP vector, pre-digested 
with BstEII (figure 17). To determine the presence of our insert into the plasmid, we screened 
the colonies obtained after transformation of DH5α bacteria with 2 restriction enzymes, 
EcoRI and EcoRV. The result expected of this digestion was 2 bands with different molecular 
weight: 4160 bp and 1806 bp. The cloned product was amplified by maxiprep and sequenced 
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with two primers (forward: 5’- TCC GCG TTA CAT AAC TTA CGG -3’; reverse: 5’- GGG 
CGT ACT TGG CAT ATG AT -3’) to ensure that no mutations had been introduced.  
 
  
Figure 17: Schematic outline of the clonage of GAMT-2 shRNA and its CMV promoter in pAAV-hrGFP 
vector. The pRNAT-CMV3.2-Neo vector containing the CMV promoter and GAMT-2 shRNA was digested by 
two restriction enzymes, BglII and XbaI, to excise the fragment of interest. After the digestion of pAAV-hrGFP 
vector by BstEII and the reaction with the Klenow enzyme, the ligation of fragment of interest with pAAV-
hrGFP was performed to obtain the insertion of CMV promoter and shRNA GAMT in pAAV-hrGFP vector. 
Amp R, Ampicillin resistance gene ; pUC ori, pUC origin of replication sequence; cGFP, corail green fluorescent 
protein; poly(A), poly-adenylation; hrGFP, humanized recombinant green fluorescent protein; L-ITR, left inverted 
terminal repeat; R-ITR, right inverted terminal repeat. 
 
 
To produce the GAMT-2 shRNA-transducing AAV particles, we have transfected three 
plasmids in AAV-293 cell cultures, (i) pHelper, (ii) pAAV-RC to produce AAV serotype 2 or 
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pDP5rs to produce AAV pseudotype 2/5, and (iii) pAAV-hrGFP empty or expressing the 
GAMT-2 shRNA. Finally, we obtained two types of AAV viruses: 1) the AAV control virus 
without shRNA sequence, with a single cassette in its genome (figure 18-A), and 2) the 
interferent AAV virus expressing the GAMT-2 shRNA sequence, with a bi-cistronic 
expression cassette in its genome (figure 18-B). 
 
 
Figure 18: Schematic representation of the single (A) and bis-cistronic (B) expression vectors used in this 
study. ITR, inverted terminal repeat ; pCMV, Cytomegalovirus promoter; X beta-globin intron; hrGFP 
humanized recombinant green fluorescent protein ; hGH pA, human growth hormone polyA signal ; shRNA, 
short hairpin RNA ; pA, poly-adenylation.  
 
 
The expression of a fluorescent reporter gene, hrGFP, was under the CMV promoter. The 
expression of the GAMT-2 shRNA was also under the control of the CMV promoter. The 
progress of AAV production could be monitored by observing phenotypic changes of the 
AAV-293 cell culture. The most obvious sign of viral production was a color change in the 
medium from red to orange/yellow, and the cells rounding up and detaching from the dish 
(figure 19). 
A. pAAV CONTROL
ITR ITRpCMV hrGFP hGH pAX
ITR ITRpCMV hrGFP hGH pA
B. pAAV-shRNA
pCMV shRNA pAX
  
 
78 
 
Figure 19: AAV particles production by the AAV-293 producer cells. A) AAV-293 cell morphology 6 hours 
after the co-transfection with the calcium-phosphate method of pHelper, pAAV-RC or pDP5rs, pAAV-hrGFP 
empty or expressing the GAMT-2 shRNA. B) AAV-293 cell morphology 3 days after the transfection. The cells 
round up and detach from the dish. The pictures were taken at 10x magnification without the removal of media 
and floating cells (Bar = 100 μm). 
 
Four days after transfection, the cell supernatant containing the produced AAV particles was 
harvested. The viral particles were purified and then titrated by an ELISA method. The range 
of viral particles was between 1x109 and 1x1011 depending on the viral production. 
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2. Transduction of monolayer cell cultures with AAV 
 
AAVs isotype 2 and pseudotype 2/5 are the most employed AAV particles to transduce neural 
cells (Burger et al., 2005; Howard et al., 2008; Xu et al., 2001) and were thus chosen for this 
study. AAV isotype 2 has a genome and a capsid of serotype 2, while AAV pseudotype 2/5 
has a genome of serotype 2 and a capsid of serotype 5. 
To test the efficiency of AAV serotype 2 and 2/5 to down regulate the expression of the 
GAMT gene, first we investigated the transduction of AAV vectors in monolayer cell 
cultures. We have chosen the C6 monolayer cell cultures as these cells expressed GAMT. The 
efficiency of the transduction was evaluated by the observation of the hrGFP expression, the 
reporter gene expressed by AAV, with a fluorescent microscope, and a western blotting was 
realized to compare the expression of GAMT protein in C6 cell cultures treated with AAV 
control or AAV expressing the best selected GAMT-2 shRNA. 
Briefly, the day before viral transduction, C6 cells were plated in dishes at 100 000 cell/dish. 
After 24 hours, the cells were transduced with AAV serotypes 2 or 2/5, either control or 
interferent to GAMT gene (AAV2-CTRL, AAV2-GAMT-2, AAV2/5-CTRL or AAV2/5-
GAMT-2). The multiplicity of infection (MOI) is the ratio of viral particles to the cells to be 
infected, and in this study we have chosen a MOI of 1000. From the fifth day, we have 
observed the cells under a fluorescent microscope, figure 20 showing representative pictures 
of transduced cells. The morphology of infected cells, observed under Nomarsky microscopy, 
was unchanged as compared to the uninfected cells. 
Depending on the cultures the proportion of AAV infected cells varied between 40 to 50% of 
the total number of cells.  
 
  
 
80 
  
Figure 20: hrGFP expression in C6 monolayer cell cultures transduced with AAV2-GAMT-2 or AAV2/5-
GAMT-2. Cells (100 000 cells/dish) were transduced with AAV2-GAMT-2 with a MOI of 1000 (A), and 
AAV2/5-GAMT, with a MOI 1000 (B) or not transduced (C).The fluorescent (A1, B1 and C1) or the Nomarsky 
pictures were recorded seven days after the transduction with AAV particles (Bar = 100 μm). 
 
 
 
 
 
To investigate the potential decrease of GAMT protein level due to the RNA interference, we 
performed western blotting to quantify the GAMT protein. For this, 15 days after the viral 
infection with AAV2 and AAV2/5 control or interferent vectors, the cells were harvested and 
the proteins were extracted. Compared to the cells infected with AAV control, the protein 
level of GAMT was decreased in cells infected with AAV2-GAMT-2 or AAV2/5-GAMT-2. 
AAV2-GAMT-2
AAV2/5-GAMT-2
A1
B1
GFP NOMARSKI
 A2
B2
C1 C2
Control
AAV2 and AAV2/5 vectors were equally able to transduce C6 cells. 
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AAV2-GAMT-2 was more efficient than the AAV2/5-GAMT-2, with a decrease of GAMT 
protein level of about 50% for AAV2, instead of 25% for serotype 2/5 (figure 21). 
 
 
Figure 21: Quantification of GAMT protein expression after 15 days of AAV infection in C6 cell cultures. 
A) Representative western blot showing the GAMT and tubulin protein levels from control cells or cells infected 
by AAV2-GAMT-2 or AAV2/5-GAMT-2. B) The level of GAMT protein was normalized with tubulin to 
correct for minor differences in total protein loading from different samples. The values represent the mean from 
2 replicate cultures.  
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AAV2 serotype appears the most effective serotype to transduce GAMT shRNA in C6 cells. 
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3. GAMT knock down in 3D reaggregated brain cell cultures 
 
In the first part of this study, we realized prelimary tests in C6 monolayer cell cultures to 
investigate the efficiency of several shRNAs to induce the knock-down of GAMT gene, 
before to develop our new experimental model in brain cell aggregates. We selectioned the 
best sequence GAMT-2 shRNA to produce serotype 2 and 2/5 AAVs to transduce brain cell 
cultures. We have demonstrated in a simple model of C6 monolayer cell cultures expressing 
GAMT that AAV serotype 2 induced the maximal knock down as compared with the results 
obtained with serotype 2/5. After having demonstrated the knockdown effect of GAMT-2 
shRNA on GAMT protein expression in C6 cells, we turned to the 3D reaggregated brain cell 
cultures. These cultures are composed of all types of brain cells, that are organized in a 3D 
network acquiring a tissue-specific pattern resembling that of the in vivo brain, and therefore 
are considered as organotypic brain cell cultures (Honegger and Monnet-Tschudi, 2001). 
As 3D primary brain cell cultures in aggregates, which are made of all the different brain cell 
types, may behave differently as compared to C6 cells, AAV serotypes and the optimal MOI 
employed may also differ to obtain a maximal knock down. Several tests were performed to 
determine the best AAV serotypes and the adequate MOI to transduce reaggregated 
developing brain cell cultures. The cultures were infected at DIV 0 by AAV-GAMT-2 
(expressing GAMT-2 shRNA) or control AAV-Empty viruses, with different MOI (10, 50, 
100, 200 or 1000). The effect of viruses on GAMT expression level was evaluated at DIV 5, 
8, 11 and 13 of culture by western blotting and qPCR. 
 
3.1. Quantification of GAMT down-regulation by western-blot 
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The effect of AAV on GAMT expression in 3D primary brain cell cultures was assessed by 
measuring the GAMT protein by western blotting. While at DIV 5, level of GAMT protein 
was very low making difficult any measure of GAMT knock down, later stages showed a 
clear expression of GAMT protein, thus allowing the evaluation of the possible decrease of 
GAMT protein. At DIV 8, the infection of AAV2- GAMT-2 with a MOI of 100 provided a 
decrease of GAMT protein of about 40%, instead of about 25% for the infection with 
AAV2/5-GAMT-2 (figure 22). Moreover, AAV2/5 appeared to have a “toxic” effect per se, 
without GAMT-2 shRNA expression, as shown on figure 22 with a decrease of about 30 % of 
GAMT protein expression in aggregates infected with AAV2/5-Empty. 
 
 
Figure 22: GAMT protein expression level after infection by serotype 2 or 2/5 AAVs (MOI: 100). 
Aggregates were harvested at DIV 8 of culture and the proteins were extracted to determine the GAMT protein 
level by western blotting. A) Representative western blot showing the GAMT level of cultures infected with 
AAV2 or AAV2/5. Samples under AAV2/5 condition come from the same blot. B) Quantification of western 
blots for GAMT protein. The level of GAMT protein was normalized with tubulin to correct for minor 
differences in total protein loading from different samples. The values represent the mean from 2 replicate 
cultures.  
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In the first part of study with aggregates infected by AAV, we selected the serotype 2 of AAV 
vectors expressing GAMT-2 shRNA to down-regulate the endogenous levels of GAMT. As 
the expression pattern of transducing AAV-based vectors in aggregates brain cell cultures are 
not known, we investigated the stability of expression of shRNA from AAV vectors by the 
harvest of aggregates at several stages after the dissection (DIV 0). The harvests were 
performed at DIV 5, 8, 11 and 13, and the proteins were extracted to realize the quantification 
of GAMT protein level by western blotting. The maximal knock down of GAMT was 
obtained at DIV 8. An infection with a MOI 100 allowed a 55% decrease of the GAMT 
protein as compared to the aggregates infected with AAV2-Empty (figure 23). At DIV 5, the 
GAMT protein was very low and we could not see any difference between the infection with 
AAV2-Empty or AAV2 transducing the GAMT-2 shRNA (data not shown). At DIV 11, the 
GAMT protein returned progressively to normal levels in aggregates infected with AAV2-
GAMT-2 (figure 23). At DIV 13, the levels of GAMT protein in aggregates infected with 
AAV2-Empty and AAV2-GAMT-2 were superior to the control condition. This observation 
might be due to an effect of AAVs on tubulin expression, as suggested by the decrease of 
tubulin in AAV-infected aggregates (figure 23). In the future, other genes not-affected by 
AAVs might be tested to normalize our experiments. 
 
Therefore, as in C6 cultures, AAV2 appeared the best serotype to allow the strongest GAMT 
RNAi effect in aggregates at day 8 of culture. 
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Figure 23: Knockdown effect on GAMT protein expression level at DIV  8, 11 and 13 after the infection by 
AAV2 with a MOI of 100. The aggregates were harvested at DIV 8, 11 or 13 of culture and the proteins were 
extracted to determine the GAMT protein level by western blotting. A) Representative western blot showing the 
GAMT level of samples infected by AAV2 at DIV 8, 11, and 13. B) Quantification of western blots for GAMT 
protein. The level of GAMT is normalized with tubulin to correct the minor differences in total protein loading 
from different samples. At DIV8 mean  SD (3<n<6; NS: non-significative; *: p<0.05). At DIV11 and DIV13, 
the values represent the mean from 2 replicate cultures.  
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The maximal GAMT RNAi effect occurs at DIV 8 of culture, while at DIV 11 and 13, 
aggregates return to a higher level of GAMT. 
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DIV 0 of culture and harvested at DIV 8. Immunoblot analysis revealed that the MOI of 10 
and 50 were not efficient to decrease the GAMT protein level (data are not shown). A MOI of 
200 allowed the most important decrease of GAMT protein level, at about 83% as compared 
to 40% with a MOI of 100 (figure 24). Moreover, we also tested a MOI of 1000, which led to 
the death of aggregates (data not shown). 
 
Figure 24: GAMT protein expression level after infection by serotype 2 AAV with a MOI of 100 or 200. 
The aggregates were harvested at DIV 8 of culture and the proteins were extracted to determine the GAMT 
protein level by western blotting. A) Representative western blot showing the GAMT level of samples infected 
by AAV2 with different MOIs, 100 or 200. B) Quantification of western blots for GAMT protein. The level of 
GAMT is normalized with tubulin to correct the minor differences in total protein loading from different 
samples. Infection with a MOI 100 mean  SD (3<n<6; *: p<0.05). Infection with MOI 200, the values represent 
the mean from 2 replicate cultures. 
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Finally we decided to observe precisely the pattern of GAMT down-regulation on consecutive 
days. The harvests were performed at DIV 5, 6, 7 and 8 after the infection by AAV2 with a 
MOI of 200, and the protein were extracted to realize quantification of GAMT protein level 
by western blotting. The results obtained at DIV 5 were not showed because the GAMT 
protein level was very low and we could not observed precisely a difference between the 
several conditions. From DIV 6 the decrease of GAMT protein level was progressive, 
reaching its maximum at DIV 8, with a decrease of 83% of GAMT protein level (figure 25).  
 
Our results showed that the MOI of 200 was more efficient that the MOI of 100 to obtain the 
maximal decrease of GAMT protein level. 
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Figure 25 : GAMT protein expression level at DIV 6, 7 and 8 after the infection by AAV2 with a MOI of 
200. The aggregates were harvested at DIV 6, 7 or 8 of culture and the proteins were extracted to determine the 
GAMT protein level by western blotting. A : Representative western blot showing the GAMT level of samples 
infected by AAV2 at DIV 6, 7, and 8. At DIV 6, the samples come from the same blot. B : Quantification of 
western blots for GAMT protein. The level of GAMT is normalized with tubulin to correct the minor differences 
in total protein loading from different samples. The values represent the mean from 2 replicate cultures.  
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Our results showed the progressive decrease of the GAMT protein level during three 
consecutive days and confirmed that the best decrease of GAMT protein was obtained at DIV 
8 after the infection by AAV2. 
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3.2. Quantification of GAMT down-regulation by qPCR 
 
In the first part of the study, we have shown the efficiency of RNAi on the GAMT protein 
level. We were also interested at analyzing the efficiency of RNAi on the GAMT mRNA 
expression. Real-time PCR, or quantitative PCR (qPCR), is a sensitive gene analysis 
technique, which combined to reverse transcription, allows the quantification of mRNA: 
qPCR allowed to evaluate the impact of shRNA on GAMT mRNA expression. The 
aggregates brain cell cultures were infected by control AAV2-Empty or AAV2-GAMT-2 at 
DIV 0 of culture with a MOI of 200, and harvested at DIV 8. The RNA was extracted and the 
cDNA was synthesized by reverse transcription to realize the qPCR (couple of primers: 
forward 5’-TAC AAA ACT GGG CCC TGA AG-3’ and reverse 5’-AGC AAA CGG AAA 
GCA TGA GT-3’). 
The results showed a decrease of 30% of GAMT mRNA in aggregates infected by AAV2-
GAMT-2 as compared to the aggregates infected by AAV2-Empty  (figure 26). 
 
Figure 26: Quantification of GAMT mRNA expression after 8 days of AAV infection in aggregates brain 
cell cultures. The qPCR was realized on the cDNA obtained by reverse transcription of aggregates harvested at 
DIV 8 of cultures. The level of GAMT gene was normalized with GAPDH gene to correct the minor differences 
in sample loading. Mean  SD (n=4; **: p<0.01). 
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3.3. Measure of extracellular GAA and Cr by tandem mass spectrometry 
 
After having demonstrated the knockdown effect of AAV2-GAMT-2 on GAMT protein 
expression and on GAMT mRNA in 3D reaggregated brain cell cultures, we were interested 
on the measure of two metabolites, GAA and Cr, to validate our new experimental model of 
GAMT deficiency in 3D reaggregated brain cell cultures. It is known that GAMT-deficient 
patients accumulate GAA in brain due to the block of GAMT enzymatic activity, with a 
concomittent decrease of their brain Cr. We wanted to verify in aggregates infected with 
AAV2-GAMT-2 if this could also be observed, with a decrease of Cr and an increase of 
GAA. The 3D reaggregated brain cell cultures were infected by control AAV2-Empty or 
AAV2-GAMT-2 at DIV 0 of culture with a MOI of 100, and harvested at DIV 5, 8, 11 and 13 
to measure extracellular GAA and Cr by the tandem mass spectrometry. 
As already demonstrated (Braissant et al., 2008), control conditions with unaffected 
aggregates showed the progressive increase of the Cr synthetic pathway along the time of 
culture, Cr levels released by brain cells in the medium being measured at 6 µM at DIV 5 but 
reaching 100 µM at DIV 13 in control condition (figure 27, A). In parallel, GAA released in 
the medium was measured at 5 µM at DIV 5, but reached 55 µM at DIV 13 in control 
condition (figure 27, B). The Cr/GAA ratio measured here (between 2 and 3.5 depending of 
the DIV) is in good correlation with the ratios measured in previous experiments in brain cell 
aggregates under control conditions (Braissant et al., 2008). 
AAV2 transducing GAMT-2 shRNA induced a decrease of 30% of GAMT mRNA in 
aggregates.  
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AAV viral toxicity (tested by TUNEL assay) could be observed, in particular at DIV 8, with 
very important increased levels of GAA (and to a less extend of Cr) in the culture medium in 
AAV2-Empty and AAV2-GAMT-2 cultures as compared to unaffected controls (figure 27, B 
and C). Viral toxicity was still visible at DIV 11, in particular on GAA level. This increase of 
released GAA and Cr in the medium may illustrate cell death induced by viral infection. No 
significant viral toxicity could be observed anymore at DIV 13 (figure 27, A and B). 
A specific effect of GAMT RNAi was observed at DIV 8 (however non-significative at this 
stage) as well as at DIV 11 and 13 (with high significativity; p<0.01) between AAV2-GAMT-
2 and AAV2-Empty cultures, with the characteristic increased GAA level due to the GAMT 
block induced by RNAi, and the concomittent decrease of Cr. Most interestingly, the increase 
of GAA and decrease of Cr at DIV 11 and DIV 13 were in stoechiometric proportions, which 
is expected also under GAMT activity inhibition (figure 27, C). 
These results validated our experimental of GAMT-deficiency model in 3D reaggregated 
brain cell cultures, the same characteristic metabolite changes being observed as in GAMT-
deficient patients. 
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Figure 27: Measure of extracellular GAA and Cr by tandem mass spectrometry within 3D reaggregated 
brain cell cultures at DIV 5, 8, 11 and 13 after infection or not by AAV2 with a MOI of 100. Measures were 
realized on aggregates harvested at DIV 5, 8, 11 and 13 of culture. Measure of Cr (A) and GAA (B) in 
aggregates infected or not by AAV2-Empty. Panels A and B illustrate the effect of AAV2 per se on Cr and GAA 
release, including a potential toxicity to brain cells ; mean  SD (n=4; NS: non-significative; for Cr: * p<0.05, 
** p<0.01, *** p<0.001; for GAA: † p<0.05, †† p<0.01, ††† p<0.001). C: Measure of Cr and GAA in 
aggregates infected by AAV2-Empty or AAV2-GAMT-2. Panel C illustrates the effect of GAMT knockdown on 
Cr and GAA release by brain cells ; mean  SD (n=4; NS: non-significative; for Cr: * p<0.05, **, p<0.01 *** 
p<0.001 ; for GAA: † p<0.05, †† p<0.01, ††† p<0.001). 
 
 
 
Our results validated the new experimental model of GAMT deficiency with a decrease of 
extracellular Cr level and an increase of extracellular GAA level in aggregates infected with 
AAV2-GAMT-2 as compared to the aggregates infected with AAV2-Empty. 
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After validating the GAMT knockdown, as shown above, in our experimental model, we 
aimed at observing the effects of GAMT knockdown in 3D reaggregated brain cell cultures. 
 
 
III. Consequences of GAMT knockdown on 3D 
reaggregated brain cell cultures 
 
 
1. Effect of GAMT knockdown on developing brain cells 
 
To analyse the effect of AAV2-GAMT-2 on 3D reaggregated brain cell cultures, we first 
examined the morphology of brain cell aggregates by immunohistochemistry against different 
cell-specific markers, namely phosphorylated medium-weight neurofilament (p-NFM, 
neurons), glial fibrillary astrocyte protein (GFAP, astrocytes) and myelin basic protein (MBP, 
oligodendrocytes). The cryosections (16 µm) were realized from aggregates harvested at DIV 
13. It appeared that the AAV2-GAMT-2 viruses had no effect on MBP expression in 
oligodendrocytes, while a strong decrease of p-NFM expression in neurons and of GFAP 
expression in astrocytes was observed (figure 28).  
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Figure 28: Perturbation in brain cell development in aggregates infected with AAVs with a MOI of 200. 
Aggregates were infected by AAVs at DIV 0 and harvested at DIV 13. Immunostaining of MBP, p-NFM and 
GFAP was realized on cryosections and revealed that the AAV2-GAMT-2 had no effect on oligodendrocytes but 
strongly affected the signal in neurons and astrocytes (Bar = 100 μm). 
 
 
 
 
2. Activation of neuronal cell death pathway by GAMT 
knockdown 
 
The effect of GAMT RNAi on cell death in 3D reaggregated brain cell cultures was assessed 
by in situ detection of apoptotic cell death using terminal desoxynucleotidyl transferase 
(TdT)-mediated dUTP nick end labeling (TUNEL) in samples harvested at DIV 8 and 11 after 
the infection by control AAV2-Empty and AAV2-GAMT-2. At DIV 8 of culture, the number 
of TUNEL-positive cells was very low in control condition not infected by AAV2 (figure 29-
A). The infection with AAV2-Empty increased the number of apoptotic cells, this result 
MBP
GFAP
CONTROL AAV2-Empty AAV2-GAMT-2
p-NFM
GAMT RNAi appears to affect neurons and astrocytes predominantly in aggregates infected 
by AAV2-GAMT-2, but not oligodendrocytes. 
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showing the death caused by the toxicity of viruses (figure 29-B). Finally, TUNEL-positive 
cells were much more numerous in cultures infected with AAV2-GAMT-2 suggesting that the 
interference of the GAMT gene induced an increase of apoptosis (figure 29-C).  
The harvest at DIV 11 showed the same results for the control condition and the aggregates 
infected with control AAV2-Empty (figure 30-A & B), with a very low number of TUNEL-
positive cells as compared to the aggregates treated with AAV2-GAMT-2. On the other side, 
the number of TUNEL-positive cells in aggregates treated with AAV2-GAMT-2 was less 
important at DIV 11 than the number of apoptotic cells at DIV 8 (figure 30-C). 
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Figure 29: Neurotoxic effects (apoptosis, necrosis) of infection by AAVs on reaggregated developing brain 
cell cultures at day 8. Untreated cultures and cultures infected by AAVs at DIV 0 and harvested at DIV 8 were 
fixed and labeled with the TUNEL method. A) control condition. B) aggregates infected by control AAV2-
Empty with a MOI of 200. C) aggregates infected by AAV2-GAMT-2 with a MOI of 200. A2, B2 and C2 are 
higher magnifications (40x) of the pictures presented in A1, B1 and C1 respectively (10x) (Bar = 100 μm). 
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Figure 30: Neurotoxic effects (apoptosis, necrosis) of infection by AAVs on reaggregated developing brain 
cell cultures at DIV 11. Untreated cultures and cultures infected by AAVs at DIV 0 and harvested at DIV 11 
were fixed and labeled with the TUNEL method. A) control condition. B) aggregates infected by control AAV2-
Empty with a MOI of 200. C) aggregates infected by AAV2-GAMT-2 with a MOI of 200. A2, B2 and C2 are 
higher magnifications (40x) of the pictures presented in A1, B1 and C1 respectively (10x) (Bar = 100 μm). 
 
 
 
A1 A2
B1 B2
C1 C2
A significant increase of apoptotic cells was observed by TUNEL labeling after 8 days of 
infection by AAV2-GAMT-2. After 11 days of infection, the amount of apoptotic cells was 
lower than at DIV 8. 
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To confirm the increase of apoptosis in aggregates infected with AAV2-GAMT-2, we 
analyzed by western blotting the full length and cleaved caspase 3 (e.g. activated caspase 3). 
Aggregates were harvested at day 8 of culture when the maximal effect of apoptosis was 
observed by TUNEL labeling. Immunoblots revealed that the cleaved caspase 3 increased in 
aggregates infected by AAV2-GAMT-2 and not in samples treated with AAV2-Empty (figure 
31). These results showed that the apoptosis induced by the activation of caspase 3 pathway 
was due to the interference on the GAMT gene and not by the toxicity of AAV viruses. 
 
Figure 31: Full length and cleaved caspase 3 protein level at DIV 8 after the infection by AAV2 with a 
MOI of 200 in aggregates. The aggregates were harvested at DIV 8 of culture and the proteins were extracted to 
determine the full length and cleaved caspase 3 protein level by western blotting. A) Representative western blot 
showing the full length and cleaved caspase 3 level of samples infected by AAV2. B) Quantification of western 
blots for the two forms of caspase 3 protein. The level of caspase 3 was normalized with tubulin to correct the 
minor differences in total protein loading from different samples. Mean  SD (n=4; NS: non-significative; **: 
p<0.01).  
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Many of the external signals encountered by cells are transduced to the nucleus by a highly 
conserved eukaryotic signaling mechanism, the mitogen-activated protein kinase (MAPK) 
cascades. Activated MAPKs phosphorylate specific substrate such as transcription factors, 
cytoskeletal elements and other protein kinases, which in turn control physiological processes 
such as gene expression, mitosis, proliferation, motility, metabolism or programmed cell 
death (Aouadi et al., 2006). We were interested in one of the major conserved groups of 
MAPK, the p38 MAPK, in 3D reaggregated brain cell cultures infected by AAV2-Empty or 
AAV2-GAMT-2 or not. The p38 MAPK pathway is activated by cytokines, UV irradiation, 
osmotic and temperature stress and growth factors (Aouadi et al., 2006). The p38 MAPK is 
also involved in apoptosis and many function both upstream and downstream of caspases in 
the apoptosis response (Ono and Han, 2000).  
On western blot, we showed that the infection with AAV2-Empty and AAV2-GAMT-2 
increased the phosphorylation of p38 MAPK as compared with the control condition (figure 
32). Consequently the AAV particles have an effect of toxicity on aggregates and caused the 
activation of cell death pathways. However, the increase of phosphorylated p38 MAPK was 
higher in aggregates treated with AAV2-Empty than in aggregates treated with AAV2-
GAMT-2 (figure 32). This result might be explained by the potential decrease of astrocytes 
and neurons under AAV2-GAMT-2, as suggested by the strong decrease observed in GFAP 
and p-NFM proteins (figure 28). This observation might also be explained by the fact that the 
activation of p38 MAPK was principally located in reactive astrocytes (Cagnon and Braissant, 
2009), the potential decrease of astrocytes under AAV2-GAMT-2 leading thus to a decrease 
Increase in activated caspase 3 confirmed the increase of apoptosis in aggregates infected by 
AAV2-GAMT-2 
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of phopho p38MAPK in aggregates infected by AAV2-GAMT-2 as compared to AAV-
Empty. 
 
 
Figure 32: Activated p38MAPK protein level at DIV 5 after the infection by AAV2 with a MOI of 200 in 
aggregates. The aggregates were harvested at DIV 5 of culture and the proteins were extracted to determine the 
activated p38 MAPK protein level by western blotting. A) Representative western blot showing the phospho 
p38MAPK level of samples infected by AAV2 or not. B) Quantification of western blots for phospho p38MAPK 
protein. The level of phospho p38MAPK was normalized with tubulin to correct the minor differences in total 
protein loading from different samples. Mean  SD (n=4; NS: non-significative; ***: p<0.001).  
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Our results showed an increase of the phosphorylation of p38 MAPK in aggregates infected 
by AAV2-Empty and AAV2-GAMT-2 and the difference between the aggregates infected by 
AAV2-Empty and AAV2-GAMT-2 might be explained by the potential decrease of 
astrocytes under AAV2-GAMT-2. 
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Part II: Study of SLC6A8 deficiency syndrome 
 
 
In parallel of the first part of this work based on the development of a model of GAMT 
deficiency in developing brain cells, we were also interested in developing an experimental 
model for SLC6A8 deficiency. The same strategy as the one used for GAMT deficiency was 
applied: (i) test of several SLC6A8 specific shRNAs with the Dual-luciferase® assay system 
and selection of the best interfering sequence to knock down SLC6A8 gene expression, (ii) 
production of AAVs expressing SLC6A8 shRNA, and (iii) analysis of the consequences of 
SLC6A8 knockdown on brain cell development.  
 
 
I. Knockdown of SLC6A8 expression 
 
 
The design of SLC6A8 RNAi in 3D rat reaggregated brain cell cultures was performed as 
described in part I, chapter I.1. (GAMT RNAi). Rat SLC6A8 ORF is composed of 1908 nt 
(genBank accession no. NM_017348.2). Three specific shRNAs for SLC6A8 ORF were 
selected with the same algorithm than used for GAMT. The 21 nt SLC6A8 shRNAs spanned 
nucleotides 1056-1076, 1462-1482, and 1002-1022, respectively, downstream from the start 
codon of SLC6A8 ORF (figure 33). 
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Figure 33: Sequences of each shRNA selectioned and their representative position on the rat SLC6A8 
ORF.  
 
 
SLC6A8-1 and -2 shRNAs were cloned into pRNAT-CMV3.2/Neo between the restriction 
site BamHI and XhoI as for the GAMT knockdown in figure 11, while SLC6A8-3 shRNA 
was cloned into pRNA-H1.3/Neo between the restriction site BamHI and HindIII (figure 11 et 
34). 
 
Figure 34: Circle map of pRNAT-H1.3/Neo (figure taken from www.genscript.com). 
 
siRNA-SLC6A8-1
siRNA-SLC6A8-2
siRNA-SLC6A8-3
GGATCCTAAAGGACTTGACCAGGTAATTTGATATCCGATTACCTGGTCAAGTCCTTTACGCTCGAG
GGATCCTTTGACCAGTCAGGCTTGAGATTGATATCCGTCTCAAGCCTGACTGGTCAAACGCTCGAG
  BamHI                       Antisense                               Loop                                  Sense                               XhoI
GGATCCCGCCTGACTGGTCAAAGCTATTCAAGAGATAGCTTTGACCAGTCAGGCTTTTTTCCAAAAGCTT
  BamHI                       Antisense                               Loop                                  Sense                          HindIII
3 1 2
SLC6A8 ORF, 1908 nt
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CMV (SLC6A8-1 and -2) or H1 (SLC6A8-3) promoters drived the expression of shRNA, and 
SV40 promoter drived the expression of the neomycin gene and cGFP. 
As in the GAMT part of the study, the different SLC6A8 shRNAs were evaluated by the 
Dual-luciferase® assay system, which required the cloning of SLC6A8 ORF downstream of 
the Renilla luciferase gene in psiCHECKTM vector (see figure 12; as for GAMT). 
 
To achieve the quantitative assessment of SLC6A8 shRNAs efficiency, ROC cells were 
transfected 24 hours after seeding in 12 well plates with three differents plasmids, the reporter 
psiCHECKTM containing the SLC6A8 ORF, the Genscript plasmid expressing the SLC6A8 
shRNA, and p-Firefly as transfection control. A shRNA for synaptotagmin 4 gene, as well as 
the psiCHECKTM vector containing the synaptotagmin 4 ORF, were used as positive control. 
The luciferase activity was recorded 48 hours after transfection. As shown in figure 35, 
SLC6A8-3 shRNA significantly down-regulated luciferase activity with a >84% decrease. 
 
 
Figure 35: Silencing of luciferase activity by different shRNAs specific for SLC6A8 open reading frame, 
and Synaptotagmin 4 (SYT4) as positive control. ROC cells were transfected with a plasmid expressing firefly 
luciferase as a reporter for normalization of transfection, a psiCHECKTM vector expressing SLC6A8 open 
reading frame (or SYT4 open reading frame) downstream of the Renilla luciferase open reading frame, and 
plasmids expressing shRNAs specific for SLC6A8 or SYT4. Luciferase activity is shown on the Y axis in 
arbitrary units (controls for SYT4 and SLC6A8: 100%). Mean  SD (n=6; ***: p<0.001). 
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After having selected the best SLC6A8 shRNA interfering sequence in monolayer cell 
cultures, our aim was to develop a new experimental model of SLC6A8 deficiency in the 
organotypic in vitro system of 3D reaggregated brain cell cultures. Like the first part for 
GAMT deficiency, we used the AAV vector system to transduce the brain cell aggregates. We 
found ourselves faced with a problem to quantify the SLC6A8 down-regulation because our 
SLC6A8 antibody became inefficient, and a lot of time was lost to change protocols or use 
other antibodies to obtain a result on western blot. We found however interesting to show the 
preliminary results obtained on the consequences of SLC6A8 knockdown on 3D reaggregated 
brain cell cultures. The experiments for SLC6A8 knockdown were realized in parallel with 
these of the GAMT knockdown.  
 
 
II. Consequences of SLC6A8 knockdown on 3D 
reaggregated brain cell cultures 
 
 
1. Effect of SLC6A8 knockdown on developing brain cells 
 
Like for the GAMT deficiency, we analyzed the effect of AAV2-SLC6A8-3 on 3D 
reaggregated brain cell cultures, by immunohistochemistry against different cell-specific 
markers, namely p-NFM (neurons), GFAP (astrocytes) and MBP (oligodendrocytes). The 
Our results suggests that SLC6A8-3 shRNA has the best efficiency to knockdown the 
expression of SLC6A8. 
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cryosections (16 µm) were realized from aggregates harvested at DIV 13. It appeared that the 
AAV2-SLC6A8-3 viruses had no effect on pNFM expression in neurons, while a strong 
decrease of GFAP expression in astrocytes and of MBP expression in oligodendrocytes was 
observed (figure 36).  
 
 
 
Figure 36: Perturbation in brain cell development in aggregates infected with AAVs with a MOI of 100. 
Aggregates were infected by AAVs at DIV 0 and harvested at DIV 13. Immunostaining of MBP, p-NFM and 
GFAP was realized on cryosections and revealed that the AAV2-SLC6A8-3 had no effect on neurons but 
strongly affected the signal in astrocytes and oligodendrocytes (Bar = 100 μm).  
 
 
 
 
 
MBP
GFAP
CONTROL AAV2/5-Empty AAV2/5-SLC6A8-3
p-NFM
SLC6A8 RNAi appears to affect astrocytes and oligodendrocytes predominantly in aggregates 
infected by AAV2/5-SLC6A8-3, but not neurons. 
 
  
 
106 
2. Activation of neuronal cell death pathway by SLC6A8 
knockdown 
 
The same strategy to detect the activation of neuronal cell death as the one used for GAMT 
deficiency was applied. The TUNEL labeling was realized in samples harvested at DIV 8 and 
11 after the infection by control AAV2-Empty and AAV2-SLC6A8-3. At DIV 8 of culture, 
the number of TUNEL-positive cells was very low in control conditions not infected by 
AAV2 (figure 37-A). The infection with AAV2-Empty increased the number of apoptotic 
cells, this result showing the death caused by the toxicity of viruses (figure 37-B). Finally, 
TUNEL-positive cells were much more numerous in cultures infected with AAV2-SLC6A8-3 
suggesting that the interference of the SLC6A8 gene induced an increase of apoptosis (figure 
37-C).  
The harvest at DIV 11 showed the same results for the control condition and the aggregates 
infected with control AAV2-Empty (figure 38-A & B), with a low number of TUNEL-
positive cells as compared to the aggregates treated with AAV2-SLC6A8-3. On the other 
side, the number of TUNEL-positive cells in aggregates treated with AAV2-SLC6A8-3 was 
less important at DIV 11 than the number of apoptotic cells at DIV 8 (figure 38-C). 
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Figure 37: Neurotoxic effects (apoptosis, necrosis) of infection by AAVs on reaggregated developing brain 
cell cultures at DIV 8. Untreated cultures and cultures infected by AAVs at DIV 0 and harvested at DIV 8 were 
fixed and immunostained with the TUNEL labeling. A) control condition. B) aggregates infected by control 
AAV2-Empty with a MOI of 200. C) aggregates infected by AAV2-SLC6A8-3 with a MOI of 200. A2, B2 and 
C2 are higher magnifications (40x) of the pictures presented in A1, B1 and C1 respectively (10x) (Bar = 100 
μm). 
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Figure 38: Neurotoxic effects (apoptosis, necrosis) of infection by AAVs on reaggregated developing brain 
cell cultures at DIV 11. Untreated cultures and cultures infected by AAVs at DIV 0 and harvested at DIV 11 
were fixed and immunostained with the TUNEL labeling. A) control condition. B) aggregates infected by control 
AAV2-Empty with a MOI of 200. C) aggregates infected by AAV2-SLC6A8-3 with a MOI of 200. A2, B2 and 
C2 are higher magnifications (40x) of the pictures presented in A1, B1 and C1 respectively (10x) (Bar = 100 
μm). 
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A significant increase of apoptotic cells was observed by TUNEL labeling after 8 days of 
infection by AAV2-SLC6A8-3. After 11 days of infection, the amount of apoptotic cells was 
lower than at day 8. 
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Cr deficiency syndromes due to AGAT, GAMT or SLC6A8 deficiencies are characterized by 
an absence or a strong decrease of Cr in CNS (Item et al., 2001; Salomons et al., 2001; 
Stöckler et al., 1994; Stromberger et al., 2003), which is the main organ affected. Indeed, no 
significative effects have been observed in peripheral tissues with high-energy demand (e.g. 
muscle and heart) in creatine deficient patients, except a faint muscular hypotonia in very rare 
cases of GAMT deficiency. So far, the mechanisms leading to the main neurological 
symptoms of these diseases are poorly understood. To understand the physiopathology of Cr 
deficiency syndromes, several in vivo models have been described so far, but their 
neurological symptoms and behavioral comportment are not comparable to those observed in 
patients. In the different mouse models, namely GAMT -/-, SLC6A8 -/- and very recently 
AGAT -/- KO mice, nothing is known so far on the neurological and behavioral effects due to 
their Cr deficiency (Schmidt et al., 2004; Skelton et al., 2011; Torremans et al., 2005; Craigen 
et al., 2011; Sinha et al., 2011). No experience has been realized at the morphological level to 
see the effect of Cr deficiency syndromes on brain cell development. 
We aimed at developing new experimental models of Cr deficiency syndromes in 3D primary 
brain cell cultures in aggregates in order to understand the disturbance in brain cell 
development, which might be responsible of some of the symptoms in patients. We observed 
the different cell types of CNS to see which were the most affected by the Cr deficiency, and 
what were the disturbances in the activation or inactivation of several pathways implicated in 
cell development or cell death. For this purpose, viral vector-mediated RNA interference was 
used to down-regulate GAMT and SLC6A8 genes in rat 3D reaggregated primary brain cell 
cultures. 
 
As 3D reaggregated brain cell cultures are composed of all brain cell types, most of them 
being post-mitotic already at the culture start, we have decided to use viral vectors to 
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transduce these cultures with the best GAMT and SLC6A8 shRNAs. We were confronted 
with some difficulties to obtain effective viral production, as most of the time the viruses 
produced were too few for the infection of the primary brain cell cultures in aggregates. We 
also suspected that sometimes the transduction was ineffective to produce a decrease of our 
gene of interest, probably because of the insufficient proportion of AAVs containing a 
genome. These two points might explain the low number of positive results obtained in this 
study. Several modifications are currently being tested in our viral production protocol to 
obtain better yields of viral particles (modifications in the proportion of plasmids allowing the 
viral production, as well as in the incubation time of the transfection solution in dishes), as the 
quality of the viral production is the major point to improve in the future to obtain a 
systematic efficient knockdown of our gene of interest.  
 
In the culture infected with AAV where we have observed a decrease of GAMT protein, we 
were confronted with another problem in the observation of GFP by microscopy. We were not 
able to observe GFP on aggregate sections while could observe the same GFP in monolayer 
cell cultures, thus proving that AAVs were able to transduce nerve cells with GFP expression. 
We have tested several methods, like fixation, or not, of our samples with paraformaldehyde 
at different %, fixation at the moment of harvest or after the cryosection. This point is the 
second point to improve in our laboratory to observe which types of cells were infected with 
AAV. 
 
The main part of this work describes our proof of principle that GAMT could be knocked 
down by RNAi through AAV transduction in 3D reaggregated brain cell cultures. We have 
shown that the serotype 2 of AAV appears more efficient to knockdown the expression of 
GAMT in brain cell cultures as compared to pseudotype 2/5, and we have demonstrated that 
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this knockdown of GAMT seems due to the specific effect of GAMT-shRNA and not to an 
off-target effect. We have validated our experimental model by measuring the GAMT protein 
and mRNA levels, as well as the concentration Cr and GAA in the extracellular medium. We 
finally have analyzed the effect of the GAMT knockdown on the development of brain cells, 
by analyzing various intracellular signaling pathways implicated in cell death, as well as brain 
cell reactivity and differenciation. 
 
Preliminary results were also obtained for the SLC6A8 knockdown, despite the fact that we 
had difficulties to fully demonstrate this knockdown. Interesting results were obtained on the 
morphology of brain cells or on the activation of cell death in aggregates infected by AAV-
SLC6A8 shRNA, which were performed at the same time as those of the aggregates infected 
by AAV-GAMT shRNA. We thought it was interesting to show here these preliminary results 
as the infection with AAV-SLC6A8 modified brain cell development differently as the 
GAMT knockdown. Ongoing work continues to clearly demonstrate the knockdown of 
SLC6A8 in brain cell aggregates. 
 
 
 
Part I: RNAi as an efficient tool 
 
 
I. shRNA silencing efficacy 
 
 
In order to realize an efficient down regulation of our gene of interest by shRNAs in neuronal 
cells cultures, we have analyzed the potential of several interfering sequences to decrease the 
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expression of GAMT and SLC6A8 genes. Despite considerable efforts to improve the 
selection of effective RNAi target sequences, including the development of various 
algorithms and the use of favourable thermodynamic properties, several shRNA sequences 
against a particular target mRNA need to be screened to obtain efficient knockdown. The dual 
luciferase reporter assay system was used to quantify the efficiency of shRNAs to down-
regulate our genes of interest in monolayer cell cultures. This system has been reported to be 
a robust siRNA screening system and to have many benefits. First, the assay can be 
performed rapidly and allow the screening of various shRNA molecules. Second, the presence 
of the control reporter allows normalization for experimental variations such as cell number, 
pipetting volume errors, and cell lysis efficiency (McNabb et al., 2005; Xu et al., 2003). 
Nevertheless, this system has some disadvantages, like the fact that the tested mRNA, being 
composed of the luciferase ORF combined to our gene of interest ORF, is a hybrid with a 
different configuration as compared with the endogenous mRNA. The secondary and tertiary 
mRNA structures are different between the extrinsic and the endogenous mRNAs, and this 
may influence the ability of the shRNA to interfere with our gene of interest. Among several 
shRNA sequences, the dual luciferase assay system allowed us to select the best sequence to 
downregulate the GAMT or SLC6A8 gene. To confirm these results, we transfected the 
plasmid expressing the selected shRNAs in monolayer cell cultures, normally expressing 
GAMT, and we observed the GAMT protein level by western blot. We obtained the same 
results as those with the dual luciferase assay system with a downregulation of GAMT gene 
expression of 83% at the protein level.   
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II. AAV as a viral vector 
 
 
We aimed at investigating the consequences of GAMT and SLC6A8 deficiency in 3D 
reaggregated brain cell cultures because the brain is the main organ affected by these 
pathologies. These cultures are composed of all types of brain cells, are organized in a 3D 
network resembling that of the in vivo brain, and therefore are considered as organotypic brain 
cell cultures (Honegger and Monnet-Tschudi, 2001). Given the complexity of this system 
growing as 3D spheres containing many different brain cells including already post-mitotic 
cells, a simple transfection of siRNA would not allow to obtain an efficient knockdown of our 
gene of interest. Only the mitotic cells on the surface of the spheres would be transfected with 
the siRNA. To obtain better results in the down-regulation of our gene, we decided to use an 
AAV viral vector as a tool for shRNA transfer in all cell types of the 3D reaggregated brain 
cell cultures, with the aim also of getting a longer effect of RNAi. In summary, AAV has 
many advantages including: 1) The ability to transduce dividing and non-dividing cells, (2) 
broad tropism, (3) lack of pathogenic and immunogenic effects and (4) long-term expression 
due to persistent episomal status (Mah et al., 2002; Shi et al., 2009; Stilwell and Samulski, 
2003). Finally, the AAV vector has the advantage of long-term RNAi effect upon single 
administration (Grimm et al., 2005; Grimm, 2009; Shevtsova et al., 2005; Xu et al., 2001). 
The major disadvantage of AAV is the complex production of virus, and the difficulty to 
obtain high titers of viral particles (Mah et al., 2002; Stilwell and Samulski, 2003). AAVs 
isotype 2 and pseudotype 2/5 are the most employed AAV particles to transduce neural cells 
due to their high efficiency to transduce these cells (Blits et al., 2010; Burger et al., 2005; 
Howard et al., 2008; Mason et al., 2010; Xu et al., 2001), and were therefore chosen for our 
study. 
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Our next aim was thus to develop methods to produce, purify and titrate the AAV particles. 
Briefly, for the production, three essential components are used to produce recombinant AAV 
vectors. The first is a transgene expression cassette flanked by two AAV2 ITRs and 
constructed in a plasmid. The second is the AAV helper function of Rep and Cap proteins. 
The third is the adenoviral helper function provided by the products of the adenovirus E2A, 
E4 and VA genes. The production involves co-transfection of AAV-293 cells with these three 
plasmids (Shi et al., 2009). The potential of AAV viral vectors is however limited by 
difficulties to produce high vector yields. We were regularly confronted with low yields that 
did not allow the following infection of aggregate cultures. Work is going on in the laboratory 
to obtain better yields in AAV production.  
 
The AAV titration was performed with an ELISA detection method, which recognizes a 
protein expressed by the capsid of the AAV particle. The limitation of this method is its 
recognition of two types of AAV particles, AAVs containing a genome and AAVs empty 
particles. Work is now going on to develop a precise qPCR test to allow the quantification of 
the AAV particles containing a genome, which are the effective ones to transduce shRNAs. 
Once the production, purification and titration of viruses were realized, we have obtained 
AAV particles ready to infect the cell cultures. Before testing the interfering potential of AAV 
vectors in the 3D reaggregated brain cell cultures, we have tested the AAV viruses on simple 
monolayer cell cultures expressing the GAMT gene to observe the potential of AAV to 
knockdown the GAMT gene expression. We observed that AAV2 and AAV2/5 particles were 
equally able to transduce C6 cells. However, AAV2 particles were more effective to 
knockdown the GAMT gene as compared with AAV2/5. Thus our production of viruses was 
able to transduce the cells and to decrease the expression of our gene of interest. After having 
demonstrated that our production of AAV virus was able to down regulate the GAMT gene, 
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we used this vector on 3D reaggregated brain cell cultures to realize an experimental model of 
GAMT deficiency. 
 
 
 
Part II: GAMT knockdown in 3D reaggregated 
brain cell cultures. 
 
 
I. Choice of optimal conditions to obtain a maximal 
knockdown of GAMT 
 
 
In this part of the study, we have developed the optimal conditions of AAV infections to 
obtain the maximal knockdown of GAMT gene in 3D reaggregated brain cell cultures. 
 
We have first compared the efficiency of AAV isotype 2 and pseudotype 2/5 to downregulate 
the GAMT gene in aggregates, with an infection at DIV 0 of culture and a MOI of 100. 
AAV2-GAMT-2 appeared as the best serotype to allow the strongest GAMT RNAi effect in 
aggregates with a decrease of about 40% as compared to pseudotype 2/5. The next 
experiments were thus performed with AAV2 vector.  
A decrease of 40% being considered as low, we have decided to improve the MOI used to 
obtain better knockdown of GAMT protein. While a MOI of 200 was more efficient than 10, 
50, or 100, and allowed a decrease of the GAMT protein of 83%, a higher MOI (e.g. 1000) 
caused the death of aggregates. It has been reported that cell death due to AAV toxicity can 
have different explanations. First, the cell loss triggered by injecting recombinant AAV 
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vectors expressing shRNA can be interpreted as a result of an off-target knockdown of other 
mRNAs or saturation of the miRNA pathway (Ehlert et al., 2010). Briefly the saturation of the 
miRNA machinery by overexpressing shRNAs inhibits endogenous miRNA processing 
(Boudreau et al., 2009; Grimm et al., 2006; Lund et al., 2004; Yi et al., 2005) with 
concomitant adverse effects on the transduced cells (McBride et al., 2008; Ulusoy et al., 
2009). In the nucleus, exogenous shRNAs can saturate the function of Exportin-5, a factor 
required for nuclear export of pre-miRNAs and shRNAs (Lund et al., 2004). Exportin-5 
expression is relatively low in brain tissue (Yi et al., 2005) as compared to other tissues, 
rendering the brain particularly sensitive to Exportin-5 function saturation.  
Secondly, AAV toxicity can be a result of a nonspecific effect due to overdosing, which can 
be seen with overexpression of any transgene and not related to the shRNA constructs (Ehlert 
et al., 2010).  
In our study the second explanation should be considered because the toxicity due to high titer 
of AAV infection was similar in aggregates treated with AAV2-Empty and with AAV2-
GAMT-2, suggesting that the phenomenon was unlikely to be a result of the shRNA 
expression. With a lower MOI, we could see this AAV toxicity in 3D reaggregated brain cell 
cultures by in situ cell death detection (TUNEL). The number of apoptotic cells in aggregates 
infected by AAV2-Empty and AAV2-GAMT-2 was higher than in the aggregates non-
infected by AAV particles. This observation of the toxicity effect of AAV might be correlated 
with the measure of metabolites in extracellular medium of 3D reaggregated brain cell 
cultures. Indeed, aggregates infected with both AAV2-Empty and AAV2-GAMT-2 showed, 
in comparison with uninfected aggregates, significative increased release of GAA and Cr in 
the culture medium at DIV 5, 8 and 11, with a maximal effect at DIV 8. This increased 
released of metabolites in the medium may illustrate the cell death observed by TUNEL 
experiments. At DIV 13, no significant change in extracellular GAA and Cr could be 
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observed anymore between AAV-infected and uninfected aggregates, as also illustrated by the 
decrease of TUNEL-labelled cells observed from DIV 11 on in AAV-infected aggregates. 
This decrease of AAV toxicity at later stages of the culture (DIV 11, DIV 13) might be due 
either to a decrease of AAV efficiency after more than 10 days of infection (transiency of 
AAV effect), a recovery of aggregates from AAV infection, or simply to the natural increase 
of the Cr synthesis pathway along time of culture (Braissant et al., 2008), which might allow 
neuroprotective effects (Braissant et al., 2002). 
We next determined the time-course of the RNAi efficiency in brain cell aggregates. We have 
performed harvests at DIV 5, 6, 7, 8, 11, and 13, and shown that the maximal knockdown of 
our gene of interest was observed at DIV 8 after the infection with AAV2-GAMT-2. From 
DIV 11 on aggregates returned to a normal level of GAMT. 
In conclusion, we have developed a recombinant AAV vector expressing a GAMT-specific 
shRNA (shRNA-GAMT-2), able to efficiently initiate RNAi against the GAMT gene, and we 
have determined the better conditions of AAV infection in 3D reaggregated brain cell cultures 
to obtain the maximal down-regulation of GAMT gene. In summary, we used the AAV 
serotype 2 with a MOI of 200, to have the maximal effect of GAMT knockdown at DIV 8 
after the viral infection. 
 
 
II. Validation of our model of GAMT deficiency in 
brain cell aggregates 
 
 
GAMT-deficient patients show an absence of Cr and an accumulation of GAA, the 
intermediate of Cr synthesis, in the brain due to the absence of the GAMT enzyme activity. In 
order to validate our new experimental model of GAMT deficiency with the RNAi method, 
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we had to show that it presents the same characteristics as those observed in the brain tissue 
of patients. 
In the optimal conditions of AAV infection, we have demonstrated that the GAMT-2 shRNA 
transduced by AAV2 was efficient to decrease the GAMT protein level from 83% at DIV 8 of 
culture in brain cell aggregates cultures. With these experiments we confirmed that AAV is an 
efficient vector to transduce shRNAs in primary 3D reaggregated brain cell cultures 
composed of different types of cells, eather dividing or already post-mitotic. On the other 
side, we also showed that this AAV-transduced knockdown was a transient mechanism as the 
GAMT protein returned to a normal level at DIV 11 and 13 post-infection. 
We were also interested to analyse the knockdown affect on the GAMT mRNA with qPCR 
method. The results obtained at DIV 8 after AAV infection were not as strong as compared 
with the results obtained by western blot. The decrease of the GAMT mRNA was 
approximately of 30% in 3D reaggregated brain cell cultures at DIV 8. Measures of GAMT 
mRNA level should be realized by qPCR at earlier days of harvest to see whether a time lag 
of the knockdown effect is observable in brain cell aggregates (figure 38). Indeed RNAi 
effects first affect mRNA, and then in turn the protein level. 
Our results by western blot and qPCR suggest the presence of this time lag in changes in 
GAMT mRNA and protein levels by RNAi, the level of GAMT mRNA at DIV 8 being 
already returning to normal levels while the effect on GAMT protein is still clearly visible, 
and while both GAMT protein have normal levels from DIV 11 onward.  
 
The final step to validate our new experimental model of GAMT deficiency was the measure 
of Cr and GAA in the culture medium by tandem mass spectrometry at DIV 5, 8, 11 and 13 
after the infection with AAV2-GAMT-2 and AAV2-Empty. The results of this measure 
confirmed that our system was a good experimental model, as the level of Cr was decreased 
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in aggregates infected with AAV2-GAMT-2 as compare to aggregates infected with AAV2-
Empty, and as the level of GAA was increased in aggregates infected with AAV2-GAMT-2. 
Interestingly moreover and as expected, we could observe, at DIV 11 and 13, an almost 
perfect stoichiometric balance between the decrease in Cr and the increase in GAA, in AAV2-
GAMT-2 as compared to AAV2-Empty. The 3D reaggregated brain cell cultures behaved 
thus as the brain tissues in GAMT-deficient patients. To complete and confirm these results 
obtained by tandem mass spectrometry, ongoing work will allow the measure of intracellular 
Cr and GAA in the aggregates infected by AAVs. 
After having validated our experimental model of GAMT deficiency, we focused on the 
effects of GAMT knockdown both on brain cell development and death.  
 
 
 
Part III: Effect of GAMT and SLC6A8 knockdown 
in 3D reaggregated brain cell cultures 
 
 
In our new experimental model of Cr deficiency, we observed by immunohistology a 
perturbation in brain cell development with an important potential loss of neurons and 
astrocytes in aggregates infected with AAV-GAMT as compared with aggregates infected 
with AAV-Empty. On the other side, we have observed an important potential loss of 
oligodendrocytes and astrocytes in aggregates infected with AAV-SLC6A8 as compared with 
aggregates infected with AAV-Empty. We could conclude that the presence of Cr seems to be 
essential for the brain development and the cell maturation. The effects observed in our brain 
cell aggregate model may appear much more deleterious than those observed in Cr-deficient 
patients, who would not survive such a potential loss of neurons and astrocytes for GAMT 
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deficiency or oligodendrocytes and astrocytes for SLC6A8 deficiency. However, we may 
speculate that similar effects may affect the brain regions that are the most affected in Cr 
deficiencies, namely cortex and basal ganglia.  
Our laboratory has realized the first study showing the localization of AGAT, GAMT and 
SLC6A8 genes in the rat brain and in different CNS cells, at the mRNA and protein levels. 
Both in the in vivo brain and in 3D reaggregated brain cell cultures, GAMT mRNA and 
protein were found expressed in neurons, astrocytes and oligodendrocytes, but particularly 
high levels were localized in oligodendrocytes (Braissant et al., 2001; Braissant et al., 2008). 
On the other side, when brain cells are under a stress or toxic environment (e.g. 
hyperammonemia), they become reactive and a modification in the expression pattern of 
GAMT can be observed, GAMT expression increasing in particular in oligodendrocytes while 
no change is observed in neurons and astrocytes (Braissant et al., 2008).  
Several hypotheses might explain the perturbation in brain cell development observed in our 
experimental model of GAMT deficiency with a potential loss of neurons and astrocytes but 
nothing on oligodendrocytes. First, the infection with AAVs might increase the reactivity of 
the cultures and increase GAMT expression in oligodendrocytes, thus rendering less effective 
on these cells. Second, AAVs might not infect oligodendrocytes, and thus no effect of RNAi 
could be observed on this type of cells. We could exclude this explanation because we 
observed an effect on oligodendrocytes in our experimental model of SLC6A8 deficiency. 
Third, the differentiation of oligodendroblast in oligodendrocytes occurs later in the 
maturation of aggregates as compared with those of neurons and astrocytes. We have 
observed that the AAV-transduced RNAi is transient, with a peak at DIV 8, a stage when 
oligodendrocytes are not mature at all. The peak of RNAi at DIV 8 might thus affect neurons 
and astrocytes in priority, while leaving oligodendrocytes non-affected. As for the second 
  
 
123 
hypothesis, this should probably be excluded as oligodendrocytes are affected in the SLC6A8 
deficiency model. 
In conclusion, reactive oligodendrocytes might be less affected by GAMT RNAi as suggested 
by the results observed by immunohistology. On the other side, GAMT RNAi might affect 
reactive neurons and astrocytes in priority, leading to accumulated GAA and thus cell 
toxicity. 
SLC6A8 mRNA and protein are found in neurons and oligodendrocytes, but are normally 
absent from astrocytes. In contrast SLC6A8 expression is induced in reactive aggregates 
(Braissant et al., 2008). These results might explain the potential loss of astrocytes in our 
SLC6A8-deficient model. Brain cells in aggregates might react following the viral infection 
by activating several mechanisms of defense, in particular an induction of SLC6A8 in 
astrocytes, leading to a susceptibility of astrocytes to SLC6A8 RNAi and the potential loss of 
astrocytes. 
After having shown the perturbation in brain cell development, we were interested in several 
cells signaling pathways implicated in cell death. First, we have observed by in situ cell death 
detection (TUNEL) that the infection with AAV-GAMT and AAV-SLC6A8 increased the 
number of apoptotic cells in 3D reaggregated brain cell cultures. This harmful effect due to 
the knockdown of GAMT could be explained by the increase of GAA generating a 
perturbation in neurotransmission of GABA, and by the decrease of Cr generating a decrease 
in high energy phosphates production and perturbation in neurotransmission. The loss of Cr 
leads to a failure in most energy-dependent processes necessary for cell survival, such as ion 
pumping, neuronal depolarization or pre-synaptic re-uptake of excitatory amino acids 
(Nicholls and Attwell, 1990). Previous research showed that GAA inhibits Na+-K+-ATPase 
activity in brain cells, which is deleterious for the cell survival (Zugno et al., 2004), and that 
an accumulation of GAA can reduce the brain antioxidant capacity, indicating the possible 
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involvement of oxidative injury in brain GAMT-deficient patient and offering an explanation 
for the pathogenic mechanisms of brain damage (Zugno et al., 2008). The loss of Cr and 
accumulation of GAA due to the knockdown of GAMT may cause neuronal death in 
aggregates by necrosis or apoptosis (Beard and Braissant, 2010; Dirnagl et al., 1999; Zhu et 
al., 2004). While the important cell loss observed at DIV8 after AAV infection may lead to 
the observed decrease of GAMT protein at this stage independently of RNAi, the normalizing 
levels of GAMT protein at DIV11 and 13 speak in favor of a transient, but efficient, specific 
GAMT RNAi at the younger stages.  
A study of our laboratory has brought the first evidence that GAA is taken up by brain cells 
through the same transporter as Cr: SLC6A8 (Braissant and Henry, 2010). A decrease of 
SLC6A8 expression may lead as under GAMT deficiency to an accumulation of GAA, which 
is very toxic for the cells, and a decrease of synthesis and transport of Cr, resulting in an 
increase of the number of apoptotic cells in cultures. 
 
We were also interested in the intracellular signaling pathway that may be altered by Cr 
deficiencies. We have observed the increase of the cleaved caspase 3 in aggregates infected 
with AAV-GAMT, by the quantification of the activated form of caspase 3 by western blot. 
The caspase family, composed of proteases, is the core component of the apoptotic machinery 
involving a proteolytic system. Two major caspase-3 activating pathways have been 
identified: an extrinsic pathway involving cell-surface receptors, and an intrinsic pathway 
resulting from alterations at the level of mitochondria (Rupinder et al., 2007). The first is 
triggered by signals extrinsic to the cell through ligation of death receptors such as Fas or 
tumor necrosis factor-alpha receptor. These ligand-activated receptors recruit a number of 
adaptor molecules to the intracellular domain of the receptor, which culminate in activation of 
the initiator caspase 8. This caspase cleaves executioner caspases such as caspase-3, which 
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cleaves a wide range of intracellular substrates to trigger the apoptotic response. The second 
major pathway activating the caspase cascade is an intrinsic cellular response to a range of 
stimuli including oxidative stress, growth factor withdrawal, UV radiations and 
chemotherapeutic agents (figure 40).  
 
Figure 39: Steps in signaling of extrinsic and intrinsic pathways of apoptosis (inspired by Rupinder et al., 
2007) 
 
The loss of Cr has consequences at the mitochondrial level because Cr plays essential roles in 
stabilizing mitochondrial function and in decreasing neuronal death. The loss of Cr, as 
observed in our experimental model, causes the dysregulation of the mitochondria with 
alterations in Ca2+ homeostasis, production of reactive oxygen species (ROS) and cell death 
(apoptosis) (Beard and Braissant, 2010; Green and Reed, 1998; McBride et al., 2006; Steeghs 
et al., 1997). A recent study has shown an overproduction of ROS due to an accumulation of 
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GAA in GAMT-deficient patient fibroblast cell lines, which may also occur in our 
experimental model and explain the very important number of apoptotic cells (Alcaide et al., 
2011). Mitochondria can release several pro-apoptotic proteins into cytosol, which in turn can 
induce cell death (Primeau et al., 2002). This release is under control of ROS, allowing 
formation of mitochondrial permeability transition pores (mPTP), a continuum between inner 
and outer mitochondrial membranes (Adhihetty and Beal, 2008). mPTP are associated with 
different death mechanisms leading to apoptosis and necrosis (Bernardi et al., 1998). mPTP 
formation and opening is facilated by several factors, like accumulation of Ca2+, reduction in 
membrane potential, increase in inorganic phosphate, decrease in ATP and ADP, and 
elevation in oxidative stress (Di Lisa and Bernardi, 2005). In particular, mPTP are localized 
on the mitochondrial membrane beside MtCK, with which they interact. MtCK suppresses 
pore opening and potentially decreases apoptotic susceptibility, which is itself stabilized by 
the presence of Cr (Adhihetty and Beal, 2008; Beard and Braissant, 2010; O'Gorman et al., 
1997). In our GAMT-deficient model with a strong decrease of Cr, the MtCK might not be 
stabilized and the mPTP might be open. Consequently the pro-apoptotic proteins might be 
released in cytosol causing the cell death (figure 41). This suggests important roles of Cr to 
protect neurons from cell death, and might explain some of the consequences of Cr deficiency 
in CNS. 
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Figure 40: Involvement of mitochondria and the Cr/PCr system in brain cell death. In GAMT-deficient 
cells, the absence of GAMT-activity causes an increase of GAA in culture medium and intracellularly, and a 
decrease of creatine (Cr) levels. The accumulation of GAA induces the impairment of mitochondria and the 
production of reactive oxygen species (ROS) by the electron transport chain. ROS inactivate mitochondrial 
creatine kinase (MtCK) by changing its octameric conformation to a dimeric inactivated form, leading to a 
secondary PCr depletion. Dimeric MtCK and ROS modify the structure of mitochondrial permeability transition 
pores (mPTP) and allow its opening, leading to the release of pro-apoptotic factors in cytosol and to cell death 
(Béard and Braissant, 2011). 
 
 
In a second part, we have observed the activation of a member of the mitogen-ativated protein 
kinase (MAPK), p38, by the quantification of the phosphorylated p38 MAPK form. The 
measure at DIV 8 after the infection with AAV vectors in 3D aggregates brain cell cultures 
showed an increase of the phosphorylated p38 MAPK in cultures infected by AAV-Empty 
and AAV-GAMT. On the other side the increase of phosphorylated p38 MAPK was higher in 
aggregates infected by AAV-Empty as compared with cultures infected by AAV-GAMT. 
This result may be reflecting the potential cellular loss in aggregates infected by AAV-
GAMT, as described above. 
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MAPKs are serine-threonine kinases that, when activated by phosphorylation, phosphorylate 
specific substrates such as transcription factors, cytoskeletal elements and other protein 
kinases, which in turn control physiological processes such as gene expression, mitosis, 
proliferation, motility, metabolism or programmed cell death (Aouadi et al., 2006). The p38 
MAPK is composed of 4 isoforms and is associated with stress responses such as cytokines 
stimulation, DNA damage and oxidative stress (Johnson and Lapadat, 2002). The p38 MAPK 
pathway is also involved in apoptotic response and is associated with the upstream and 
downstream activation of effector caspases, including caspase 3 (figure 40) (Ono and Han, 
2000). 
This interconnection between the caspase 3 and p38 MAPK signaling pathways might 
contribute to the strong increase of cleaved caspase 3 and the important number of apoptotic 
cells observed in aggregates infected with AAV-GAMT.  
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Chapter V: Conclusion and perspectives 
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At the start of the project, in 2007, the only available in vivo model for Cr deficiencies was 
the GAMT-/- KO mouse (Schmidt et al., 2004), which revealed only mild cognitive 
impairment and no severe neurological symptoms. We thus chose another strategy with the 
aim of developing new in vitro models of Cr deficiencies making use of organotypic 3D 
reaggregated developing brain cell cultures in which AGAT, GAMT and SLC6A8 genes 
would be knocked down by using RNAi. These models would allow a better understanding of 
the cellular, molecular and biochemical pathways altered in the developing brain cells under 
Cr deficiency. It must be emphasized that these brain cell aggregates are devoid of 
vascularization and do not develop BBB, thus limiting the analysis of Cr deficiencies to CNS 
intercellular interactions. 
 
The first step of the project was thus the development of the RNAi technique to knockdown 
GAMT or SLC6A8 genes in the brain cell aggregates, making use of AAVs expressing GFP 
to transduce specific shRNAs. The effective decrease in GAMT or SLC6A8 mRNAs and 
proteins were analyzed during the whole lifetime of the cultures, and we could determine the 
culture stages showing the maximal decrease of GAMT or SLC6A8 expression. During this 
work, a lot of difficulties were encountered, in particular to obtain important yields of 
efficient AAVs that would be sufficient to transduce the cultures, and to be able to observe 
GFP expression in the AAV-transduced cells. These technical difficulties explain the low 
number of valid knocked down experiments obtained, and consequently the low number of 
samples which, in many of the data presented, did not allow a statistical analysis of the data. 
Our work however demonstrates the proof of principle that GAMT and SLC6A8 genes can be 
knocked down by RNAi through AAV transduction in 3D reaggregated brain cell cultures. 
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The second step of the project allowed the validation of our GAMT deficiency model, first by 
showing the semi-quantitative decrease of GAMT mRNA and protein in AAV-transduced 
brain cell aggregates, and second by measuring the awaited increased GAA and decreased Cr 
by tandem mass spectrometry, as observed in the brain tissue of GAMT-deficient patients. 
 
The third part of our work allowed to further analyze the developmental effects of GAMT or 
SLC6A8 knockdowns in brain cells, demonstrating in particular differential effects of GAMT 
and SLC6A8 deficiencies on the different types of brain cells, an increase of apoptosis in 
brain cells under Cr deficiencies (increase of activated caspase 3), and an alteration of 
intracellular signaling pathways (p38 MAPK). 
 
 
The main objective in the near future is the improvement of the developed tools to allow a 
better knock-down of AGAT, GAMT or SLC6A8 genes in brain cell aggregates: 
 
The production of AAV particles has to be improved to allow efficient infections and 
transduction of brain cell aggregates. In particular, another way of titrating AAV viral 
particles at the level of their genome, making use of RT-PCR, complementary to the ELISA 
technique used in this work to titrate the viral particles based on their capsides, will allow an 
estimation of the yield of AAVs that will be efficient to transduce RNAi. AAV2 and AAV2/5 
particles have been used in this work, and other AAV serotypes will be tested to analyze 
which AAV serotypes are the most efficient to transduce brain cells, and whether they 
transduce the different brain cell types differentially. This work is actually going on in the 
laboratory. 
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The development of a method to observe GFP in AAV-transduced brain cell aggregates is 
actually going on also in the laboratory, that will allow a better follow-up of the AAV-
transduced brain cells undergoing RNAi. Preliminary results show now that GFP is clearly 
detectable in AAV-transduced brain cell aggregates.  
 
Finally, to improve the validation of the GAMT and SLC6A8 deficiency models developed in 
this work, intracellular and extracellular measures of Cr and GAA will be realized by tandem 
mass spectrometry, in complement of the extracellular measures performed for GAMT 
deficiency in this study. 
 
In GAMT (and AGAT) RNAi, treatment of AAV-transduced aggregates with Cr will be 
performed to try to correct Cr deficiency, as it is done for AGAT- and GAMT-deficient 
patients.  
 
The use of AAV-transduced brain cell aggregates that knock down the expression of AGAT, 
GAMT or SLC6A8 opens new perspectives in the understanding of primary creatine 
deficiencies, and in their therapeutic approach: 
 
AGAT, GAMT and SLC6A8 RNAi in 3D brain cell aggregates will be used to further 
understand the physiopathology of Cr deficiencies, to know which CNS cell types are the 
most affected, and which downstream signaling pathways are altered. As Cr plays essential 
roles in energy homeostasis, focus will be put on the alterations of energetic metabolism in 
brain cells induced by Cr deficiency, and how it affects brain cell development and 
differentiation. As Cr and GAA affect GABAergic neurotransmission and as Cr has been 
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suggested recently even as a true neurotransmitter, the ways Cr deficiencies affect the 
different neurotransmission systems will also be investigated. 
 
Our experimental model will also be used in therapeutic perspectives. Apart of the Cr 
treatments of AGAT and GAMT-deficient aggregates (as described above) performed to try 
the correction of the Cr deficiency (as in patients), Cr-deficient 3D brain cell aggregates will 
be used to screen Cr analogs that are developed to bypass the transport of Cr through 
SLC6A8, and analyze their therapeutical potential on Cr-deficient brain cells. In that case, 
only the effects on brain cells will be tested, as aggregates are devoid of BBB.  
 
Finally, our experimental models making use of AAV may be further develop to test a future 
gene therapy for Cr deficient patients. AAVs are currently developed in many studies as tools 
of gene transfer for the treatment of genetic neurological disorders. AAVs appear to allow 
gene delivery into CNS and brain post-mitotic cells for long periods with minimal to no 
toxicity. AAV vectors as developed in our study may be further engineered to transduce Cr-
deficient brain cells in order to correct them with the normal AGAT, GAMT or SLC6A8 
genes.  
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